TAKEDA PHARMACEUTICALS
PROTOCOL
A Phase 1b Study to Evaluate the Safet y, Pharmacokinet ics, and Pharmacodynamics of TAK -079 
in Combination Wit h Standard Background Therapy  in Patients Wit h Moderate to Severe 
Systemic Lupus Ery thematosus
Study Identifier: TAK-079-2001
Compound: TAK-079
Date: 19 February 2019
Version/Amendment 
Number:01
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 2of 110
Protocol Incorporating Amendment No 01 19 February 2019
TABLE OF CONTENTS
1.0 STUDY SUMMARY ...................................................................................................... 7
Protocol  Amendment 01 Summary  of Changes ........................................................ 10 1.1
2.0 STUDY SCHEMATIC .................................................................................................. 12
3.0 SCHEDULE OF ST UDY PROCEDURES .................................................................... 14
4.0 INTRODUCTION ......................................................................................................... 20
4.1 Background ............................................................................................................. 20
Rationale for Propos ed Study ................................................................................... 21 4.2
Rationale for Study  Design, Dose, and Endpoints .................................................... 22 4.3
4.3.1 Rationale of Study  Design ........................................................................... 22
4.3.2 Rationale for Sel ected Pati ent Popul ation.................................................... 22
4.3.3 Rationale for Dose ...................................................................................... 23
4.3.4 Rationale for Endpoints ............................................................................... 24
Benefit -Risk Profile ................................................................................................ .24 4.4
Benefit s and Risks Conclusio ns............................................................................... 26 4.5
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 27
Object ives................................................................................................................ 27 5.1
5.1.1 Primary Object ive....................................................................................... 27
5.1.2 Secondary  Object ive................................................................................... 27
5.1.3 Exploratory  Objectives ................................................................................ 27
Endpoi nts................................................................................................................. 27 5.2
5.2.1 Primary Endpo int........................................................................................ 27
5.2.2 Secondary  Endpo ints................................................................................... 27
5.2.3 Exploratory  Endpo ints................................................................................. 27
6.0 STUDY DESIGN AND DESCRIPTI ON....................................................................... 29
Study  Design ........................................................................................................... 29 6.1
Study  Drug .............................................................................................................. 29 6.2
6.2.1 Prem edicat ion............................................................................................. 30
6.2.2 Post-dose Medicat ions................................................................................. 30
6.2.3 TAK -079 and Matching Placebo Administration ......................................... 31
6.2.4 Rescue Therapy ........................................................................................... 31
Study  Stopping Rules ............................................................................................... 32 6.3
6.3.1 Assessment and Criteria for Terminating Pat ient Dosing ............................. 32
6.3.2 Assessment and Criteria for Terminating Cohort Advancement ................... 35
Precauti ons and Restri ctions.................................................................................... 35 6.4
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 3of 110
Protocol Incorporating Amendment No 01 19 February 2019
6.4.1 Pregnancy and Lactation ............................................................................. 35
6.4.2 Drug Interactions ........................................................................................ 35
6.4.3 Interference wit h Serol ogical Testing .......................................................... 35
Management of Events of Clinical Interest ............................................................... 36 6.5
6.5.1 Hypersensi tivity Reacti ons: Infusio n and Inject ion Site Reacti ons............... 36
6.5.2 Cytokine Release Syndrome ........................................................................ 38
6.5.3 Hem atologic Effects .................................................................................... 39
6.5.4 Infections .................................................................................................... 40
6.5.5 Antidrug Ant ibody Interacti ons................................................................... 40
6.5.6 Overdose ..................................................................................................... 40
7.0 SELECTION AND DISCON TINUATION/WITHDRAWAL OF SUBJECTS .............. 41
Inclusio n Cri teria..................................................................................................... 41 7.1
Exclusio n Cri teria.................................................................................................... 42 7.2
Excluded and Dose -Limi ted Medicat ions................................................................ .45 7.3
Criteria for Di scontinuati on or Wi thdrawal  of a Patient ............................................ 46 7.4
Procedures for Discont inuat ion or Withdrawal o f a Patient ...................................... 46 7.5
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 47
Clinical Study  Drug ................................................................................................ .47 8.1
8.1.1 Clinical Study  Drug Labeling ...................................................................... 47
8.1.2 Clinical Study  Drug Inventory , and Storage ................................................ 47
8.1.3 Clinical Study  Drug Blinding ...................................................................... 48
8.1.4 Randomization Code Creation and Storage ................................................. 48
8.1.5 Clinical Trial Blind Maintenance/Unblinding Procedure ............................. 49
8.1.6 Accountabilit y and Destructi on of  Sponsor -Supplied Drugs ........................ 49
9.0 STUDY PROCEDURES ............................................................................................... 51
Administrative Procedures ....................................................................................... 51 9.1
9.1.1 Informed Consent Procedure ....................................................................... 51
9.1.2 Assignment of Rando mizat ion Numbers ..................................................... 51
9.1.3 Study  Drug Assignment .............................................................................. 51
Clinical Procedures and Assessments ....................................................................... 51 9.2
9.2.1 Inclusio n and Exclusio n.............................................................................. 51
9.2.2 Medical History  and Dem ography ............................................................... 51
9.2.3 Concomitant Medications and Procedures ................................................... 52
9.2.4 Physical Examinat ion.................................................................................. 52
9.2.5 Vital Signs.................................................................................................. 52
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 4of 110
Protocol Incorporating Amendment No 01 19 February 2019
9.2.6 12-Lead Electrocardiogram ......................................................................... 53
9.2.7 AE Monitoring ............................................................................................ 53
9.2.8 Laboratory  Procedures and Assessments ..................................................... 53
9.2.9 Pregnancy Test ............................................................................................ 55
Pharm acokinet ic, and Pharmacodynamic Samples ................................ .56 9.3
9.3.1 Pharmacokinet ic Measurements .................................................................. 56
9.3.2 Immunogenici ty Samples and assessments .................................................. 56
9.3.3 56
9.3.4 57
End-of-Study  Assessments ....................................................................................... 57 9.4
10.0 ADVERSE EVENTS .................................................................................................... 59
Pretreatment Events ................................................................................................ .59 10.1
Definit ions and El ements of AEs ............................................................................. 59 10.2
10.2.1 SAEs ........................................................................................................... 61
10.2.2 AEs of Clinical Interest ............................................................................... 62
10.2.3 Assigning Severit y/Intensit y of Adverse Events .......................................... 62
10.2.4 Assigning Causalit y of Adverse Events ....................................................... 63
10.2.5 Collect ion and Reporti ng of AEs, SAEs, and AEs of Clinical Interest ......... 63
10.2.6 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  
Authori ties.................................................................................................. 65
Drug Safet y Moni toring Board ................................................................................. 65 10.3
11.0 STATISTICAL METHODS .......................................................................................... 66
Statistical and Analyt ical Plans ................................................................................ 66 11.1
11.1.1 Analysis Sets ............................................................................................... 66
11.1.2 Analysis of Demography  and Other Baseline Characterist ics....................... 66
11.1.3 Immunogenici ty Analysis ............................................................................ 67
11.1.4 Pharmacokinet ic Analysis ........................................................................... 67
11.1.5 Pharmacodynamic Analysis ........................................................................ 67
11.1.6 Safety Analysis ........................................................................................... 67
Interim Analysis and Criteria for Early Terminat ion................................................ 68 11.2
Determinat ion of Sample Size .................................................................................. 68 11.3
12.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 69
Study  Site Moni toring Visits .................................................................................... 69 12.1
Protocol  Deviat ions.................................................................................................. 69 12.2
Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 69 12.3
13.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 70
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 5of 110
Protocol Incorporating Amendment No 01 19 February 2019
IRB and/or IEC Approval ........................................................................................ 70 13.1
Subject Informat ion, Informed Consent, and Subject Authorizat ion......................... 71 13.2
Subject Confidentialit y............................................................................................ 72 13.3
Publi cation, Di sclosure, and Clinical Trial Registration Policy ................................ .72 13.4
13.4.1 Publicat ion and Disclosure .......................................................................... 72
13.4.2 Clinical Trial Registration ........................................................................... 73
13.4.3 Clinical Trial Result s Disclosure ................................................................ .73
Insurance and Co mpensation for Injury .................................................................... 73 13.5
14.0 ADMINISTRATIVE AND R EFERENCE INFORMATION ......................................... 74
Administrative Informat ion...................................................................................... 74 14.1
14.1.1 Study  Contact Informat ion.......................................................................... 74
14.1.2 Invest igator Agreement ............................................................................... 75
14.1.3 Study-Related Responsibilit ies.................................................................... 76
15.0 LIST OF ABBREVIATION S........................................................................................ 77
16.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 79
CRFs (El ectronic and Paper) .................................................................................... 79 16.1
Record Retention ..................................................................................................... 79 16.2
17.0 REFERENCES .............................................................................................................. 81
18.0 APPENDICES ............................................................................................................... 83
LIST OF IN -TEXT TABLES
Table 3.a Schedule of Study  Events: Dosing Period ........................................................... 14
Table 3.b Schedule of Study  Events: Safet y Follow -up and Long -term Safety  Follow-up 
Periods............................................................................................................... 17
Table 3.c Pharmacokinet ic, CD38, TBNK Samples, and ECG Times by Visit ................... 18
Table 6.a TAK -079 Dosing by  Study  Cohort ..................................................................... 30
Table 6.b Summary  of Dosing Criteria .............................................................................. 33
Table 7.a Excluded Medicat ions........................................................................................ 45
Table 7.b Dose -Limited Conco mitant Medicat ions............................................................ 45
Table 9.a Clinical Chemistry  and Hematol ogy Assessments .............................................. 54
Table 9.b Clinical Urinalysis Assessments ......................................................................... 55
Table 9.c End-of-Study  Clinical  Parameters ...................................................................... 58
Table 10.a General List of Takeda Medically Significant AEs ............................................. 62
Table 10.b AE Definit ions for Severi ty/Intensi ty by Category ............................................. 62
Table 10.c AE Definit ions for Causalit y.............................................................................. 63
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 6of 110
Protocol Incorporating Amendment No 01 19 February 2019
LIST OF IN -TEXT FIGURES
Figure 2.a TAK -079-2001 Study  Cohort Reviews ............................................................... 12
Figure 2.b TAK -079- 2001 Study  Schemat ic........................................................................ 13
LIST OF APPENDICES
Appendix A Pregnancy and Contraception ............................................................................. 83
Appendix B Clinical Signs and Symptoms of Cytokine Release Syndrome ............................ 87
Appendix C Grading System for Cy tokine Release Syndrome ............................................... 88
Appendix D Responsibilit ies o f the Invest igato r................................
..................................... 89
Appendix E Invest igator Consent to the Use of Personal Information .................................... 91
Appendix F Elements of the Subject’s Informed Consent ...................................................... 92
Appendix G Dose Modeling of TAK-079 .............................................................................. 95
Appendix H Detailed Descript ion of Amendment to Text ...................................................... 99
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 7of 110
Protocol Incorporating Amendment No 01 19 February 2019
1.0 STUDY SUMMARY 
Name of Sponsor:
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of 
Takeda Pharmaceutical Company LimitedCompound:
TAK -079
Study Identifier: TAK -079-2001 Phase: 1b
Protocol Title: A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK -079 in 
Combination With Standard Background Therapy in Patient s With Moderate to Severe Systemic Lupus 
Erythematosus
Background:
Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease characterized by dysregulation of T and B 
lineage cells, as well as other components of the innate immune system. A hallmark of the disease is the production of 
pathogenic autoantibodies to dou ble-stranded DNA (dsDNA), phospholipids, blood cells, and other targets. Tissue 
damage in SLE is caused primarily by these pathogenic autoantibodies through immune complex deposition with Fc -
and complement -mediated inflammation, as well as through direct antibody -target interactio ns.
The therapeutic agents that are used for treatment of SLE have demonstrated limited success in targeting autoantibod y 
productio n. Short -lived plasmablasts (PB), plasma cells (ie, terminally differentiated B cells), and long -lived plasma 
cells produce the characteristic pathogenic autoantibodies and are therefore critically involved in SLE pathogenesis. 
CD38 is a type II glycoprotein that is highly and uniformly expressed on antibody -producing PBs and plasma cells, 
making it a potential target for treatment of SLE. TAK -079 is a fully human IgG1 mAb that binds with high affinity to 
CD38. The available nonclinical and clinical data demonstrate an acceptable safety profile and encouraging 
pharmacodynamic (PD) effects in reducing ta rget cells expressing CD38. Therefore, TAK -079 is proposed to be 
investigated for potential treatment of adult patients with moderate to severe SLE.
Trial Design:
This multicenter, phase 1b study is designed to further elucidate the proof of mechanism and potential biologic activity 
of TAK -079 in a study population with moderate to severe SLE. The study design allows for the evaluation of the 
safety and biologic activity of TAK -079 or matching placebo in combination with stable SLE background therapy.
Seque ntially  enrolling, dose -escalating cohorts will allow for the evaluation of TAK -079 dosing in a step -wise, 
double -blinded design, thereby providing for both an intracohort and cross -cohort analy sis of active TAK -079 and 
matching placebo. The dosing regimen will consist of a single subcutaneous (SC) injection, of either TAK -079 or 
matching placebo, to be administered every 21 days (ie, 3 weeks) over the course of a 12 -week dosing period, for a 
maximum 4 study doses, in combination with a stable principal inv estigator –directed background therapy for SLE. 
After the 12 -week dosing period, patients will continue on study for a 12-week postdose safety follow -
up period, 
allowing for continued observation and assessment of safety and sustainability of biologic activ ity. Patients whose 
protocol -defined safety parameters do not return to adequate protocol -defined rebound levels by the end of the safety 
follow -up period will progress to a long -term follow -up period for continued monitoring. These continued safety 
observ ation periods provide optimal oversight and assessment of any ongoing study -related sequela.
Takeda clinicians/designees will provide ongoing safety oversight and surveillance throughout the study dosing 
period. As such, TAK -079 clinicians/designee will re ceive and trend all reported adverse events (AEs) and serious 
adverse events (SAEs), and a blinded review of all safety data will be conducted periodically throughout the study. 
Based on the outcomes of the Takeda safety reviews and in accordance with pred efined criteria, decisions about the 
dosing regimen for current cohorts will be implemented.
As such, before each study dose, principal investigators will provide the medical monitor with a summary of 
assessment outcomes associated with the dosing criteria for review and approval. In instances where clinical 
parameters do not meet dosing criteria, study dosing will be temporarily withheld until parameters meet 
protocol -defined dosing levels. 
An assessment of safety trends and potential risks associated wit hin and across dosing cohorts will be conducted near 
the completion of each cohort. Based on these findings, and in alignment with protocol -defined dose determination 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 8of 110
Protocol Incorporating Amendment No 01 19 February 2019
and coho rt dose -escalatio n stoppage criteria, the study may: (1) advance enrollment to th e next cohort at the next 
protocol -defined dose level, (2) advance enrollment in the next cohort at a reduced intermediate dose level, (3) expand 
enrollment at the current dose level, or (4) enact early termination of the study.
Study Primary Objective:
The primary objective of this study is to evaluate the safety and tolerability of TAK -079 in comparison with matching 
placebo, administered once ever y 3 weeks over a 12 -week dosing period in patients with active SLE who are receiving 
stable background ther apy for SLE.
Secondary Objectives:
The secondary objective of this study is to assess the pharmacokinetics (PK), PD, and immunogenicity of TAK -079 
administration over a 12 -week dosing period.
Study Subject Population: The study  population is limited to p atients with SLE who exhibit moderate to severe 
disease with persistent disease activity, who have not responded adequately to standard SLE background therapy 
treatment, and have not recently had an acute flare that was moderate to severe in nature. 
Planned Number of Subjects: 24 subjects Planned Number of Sites: 20 sites
Dose Levels by 3 Sequentially Enrolling Cohorts
Cohort A: (n = 6) TAK -079 dosed 45 mg
Cohort B: (n = 6) TAK -079 dosed 90 mg
Cohort C: (n = 6) TAK -079 dosed 135 mg
Each cohort will e nroll an additional 2 patients 
randomized to matching placeboRoute of Administration:
Subcutaneous injection
Duration of Treatment:
Dosing period: 12 weeksPlanned Trial Duration :
Total study participation : 24 to 36 weeks (approximately 6 
to 9 months) 
Total study duration : 18 to 24 months
Main Criteria for Inclusion:
To be eligible for study participation, patients must: 
Be aged 18to75 years at the time of signing the study informed consent. 1.
Meet either the 2012 Systemic Lupus International Collabor ating Clinics criteria or the American College of 2.
Rheumatology criteria for SLE diagnosis.
Have a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI -2K) score ≥6. 3.
Be positive for anti -dsDNA antibodies and/or antiextractable nuclear antigens a ntibodies. 4.
Main Criteria for Exclusion:
The following criteria will deem the patient ineligible for study participation:
An opportunistic infection ≤12 weeks before initial study dosing or is currently undergoing treatment for a 1.
chronic opportunistic infection, such as tuberculosis, pneumocystis pneumonia, cytomegalovirus, herpes simplex 
virus, herpes zoster, or atypical mycobacteria.
An acute or chronic infection requiring hospitalization ≤30 days before the screening visit and/or administration 2.
of pa renteral (intravenous [IV] or intramuscular) antibacterial, antiviral, antifungal, or antiparasitic agents ≤30 
days before the screening visit. 
Drug -induced SLE and any other rheumatologic or autoimmune disease (excluding secondary Sjögren syndrome, 3.
and m ixed connective tissue disease).
Active neuropsychiatric SLE (eg, new or worsening impaired level of consciousness; psychosis; delirium or 4.
confusional state; grand mal seizure [including status epilepticus]; aseptic meningitis, ascending or transverse 
myel itis; cho rea, cerebellar, ataxia, or demyelinating syndromes) that has required therapeutic 
intervention ≤60days before initial study dosing. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 9of 110
Protocol Incorporating Amendment No 01 19 February 2019
Protocol -defined active glomerulonephritis with concurrent acute renal flare or with documented acute renal flar e 5.
in the previous 3 months that has required lupus nephritis induction therapy.
A positive hepatitis B surface antigen or hepatitis C antibody, or HIV antibody/antigen. 6.
Concurrent medical condition that, in the opinion of the investigator, could confound i nterpretation of results or 7.
affect the patient’s ability to fully participate in the study.
Laborato ry test values outside of the limits for the tests specifically defined in the protocol. 8.
Concomitant medications that do not meet the protocol criteria (wi th regard to excluded and dose -limited 9.
medications).
Main Criteria for Evaluation and Analyses:
The primary endpoints of this study will evaluate the safety and tolerability of TAK -079 to include the incidence, type, 
and grade of AEs, as well as the percentage of patients with ≥1AE leading to study treatment discontinuation.
The secondary endpoints will be assessed through evaluation of the following parameters: 
PK evaluations of TAK -079. 1.
PD evaluations of TAK -079. 2.
Assessment of immunogenicity of TA K-079. 3.
Statistical Considerations:
The safety analysis set will consist of all patients who are enrolled and received at least 1 dose of study drug. All 
pretreatment events (PTEs) and treatment -emergent adverse events (TEAEs) will be coded by system of or gan class 
and preferred term using the Medical Dictionary for Regulatory Activities. TEAEs with an onset occurring during the 
dosing period and safety follow -up periods will be listed and included in the summary tables. Summary tables will 
include TEAEs an d drug -related AEs, the relationship of AEs to study drug (related vs not -related), grade, and 
severity of AEs. AEs leading to study drug discontinuation and SAEs will be listed. 
Sample Size Justification: 
This study is not statistically powered for any hypothesis testing. The sample size for each study cohort are considered 
to be sufficient to fulfill the study objectives of the evaluation of safety, tolerability, and pharmacokinetics of each 
cohort.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 10of 110
Protocol Incorporating Amendment No 01 19 February 2019
Protocol Amendment 01 Summary of Changes 1.1
Rationale for Amendment 01
This document describes the changes to the protocol incorporating Amendment 01. The primary 
reason for the amendment is to adjust T -cell laboratory levels for dosing criteria to better take into 
consideration the clinical setting for pati ents wi th SLE on background therapy , the pati ent’s 
baseline value, and the quant ification o f important changes fro m baseline as safet y endpo ints. 
Minor grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the study  are included for clarificat ion and administrative purposes only. 
For specific descript ions of the text changes and where the changes are located see Appendix H. 
Changes in Amendment 01
Clarificat ion that the assessment of systemic lupus erythematosus antibodies (Ab) is expected 1.
at baseline.
Clarificat ion that no dosing criteria assessments are to be conducted as part of screening. 2.
Removal of redundant RNA sampling schedule in Table 3.a. 3.
Addit ion of a one- day window (+/ -1 day ) for visits: HV7, HV8 and HV9, has been added for 4.
consistency wit h other visits.
Removal of details for urine sample collection . 5.
Clarificat ion of T -cell safety  parameters as they  pertain to dosing criteria. This clarificat ion 6.
takes into considerat ion the natural history of SLE on background therapy, the pat ient’s T-cell 
baseline values, as well as changes fro m baseline that would warrant the continuat ion or 
holding of a dose of TAK -079.
Changes to dosing criteria in the event of infusion rel ated reacti on, to better align actions with 7.
the appropriate grading cr iteria. Grade 2 or hi gher reacti ons st ill require dose discont inuat ion.
Clarificat ion of dosing criteria in the event of hypersensit ivity-related events, to better align 8.
with the CTCAE cri teria for allergic react ions, as originally intended. Any symptom of an 
anaphylactic reaction cont inues to require TAK -079 discont inuat ion.
Clarificat ion that Commo n Termino logy Cri teria for Adverse Events versio n 4.03 must be 9.
used in the study .
Clarificat ion of excluded and dose limited concomitant medications. 10.
The addit ion of  a protocol  subsect ion to provide clarification regarding potential interference 11.
with serol ogical  testing.
Clarificat ions made regarding the management of hypersensit ivity react ions to better align 12.
with the CTCAE cri teria for allergic react ions, as or iginally intended.
Removal of any reference to an unblinded pharmacist. 13.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 11of 110
Protocol Incorporating Amendment No 01 19 February 2019
Clarificat ion that ECGs are to be read locally, to include readings of triplicate 14.
electrocardi ogram s for saf ety assessments. Otherwise, triplicate ECGs will be submitted for 
subsequent central  reading at a future time.
Clarificat ion of Coombs testing to be analyzed by local labs; wit h further clarificat ion that all 15.
other l aboratory  tests, unl ess otherwise noted, should be submitted for central analysis.
Adjustments to pregnancy test met hodol ogy during screening and just prior to the first dose of 16.
TAK -079, th ough 2 negat ive pregnancy tests are still needed prior to dosing. Details about the 
durati on of  continued contraception after the last dose of study  medicat ion have been added.
Removal of British Isles Lupus Assessment Group assessments and all associated trainings 17.
and site/study  activities.
Clarificat ion that the statist ical analysis plan will be prepared before database lock. 18.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 12of 110
Protocol Incorporating Amendment No 01 19 February 2019
2.0 STUDY SCHEMATIC
Figure 2.a TAK -079-2001 Study Cohort Reviews
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 13of 110
Protocol Incorporating Amendment No 01 19 February 2019
Figure 2.b TAK -079-2001 Study Schematic
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 20of 110
Protocol Incorporating Amendment No 01 19 February 2019
4.0 INTRODUCTION
4.1 Background
Systemic lupus erythematosus (SLE) i s a seri ous condi tion that has defied efforts to develop 
effect ive therapies, leaving a significant unmet medical need for patients with moderate to severe 
disease. During the past several decades, more than 30 promising, strategically targeted bi ologics 
have entered early development for the treatment of lupus; however, only belimumab has 
successfully co mpleted a phase 3 program to obtain regulatory  approvals worl dwide [1]. These 
failures, which may  be partially attri buted to heterogeneit y in the pathophysio logy of SLE, 
indicate the need for the development of more effective targeted therapeutics. 
SLE is a heterogenous autoimmune disease characterized by dysregulat ion of 
TandBlineage cells, as well as other components of the innate immune system. A hallmark of the 
disease is the production of pathogenic autoantibodies to double -stranded DNA (dsDNA), 
phospho lipids, blood cells, and other targets. Tissue damage in SLE is caused primarily by these 
pathogenic autoantibodies through immune complex deposit ion with Fc-and 
complement -mediated inflammat ion, as well as through direct ant ibody -target interacti ons [2]. 
Virtually any organ or sy stem  in the bo dy can be affected by  SLE [3,4] .
The clinical course of SLE is episodic, with flares of disease activit y that l ead to increased 
disabili ty and organ dam age ove r time. For m oderate to severe cases, the current standard of care 
includes off -label therapies, including immunosuppressants (azathioprine, cyclophosphamide, and 
mycopheno late mofetil), high -dose steroi ds, and intravenous (IV) immunoglobulin for cy topeni a
.
The therapeutic agents that are used for treatment of SLE have demonstrated limited success in 
targeting autoantibody  producti on. Short -lived plasmablasts (PB), plasma cells (ie, terminally 
different iated B cells), and long -lived plasma cells produce the characteristic pathogenic 
autoantibodies and are therefore crit ically involved in SLE pathogenesis. 
Studi es have shown an increased number of PBs in the blood of pat ients with active SLE [3]. 
Rituximab (ant i
-CD20) and belimumab (ant i-BLys) target B cells, interrupting the release of 
newly generated PBs fro m 
memo ry B cells that are depl eted by  the drugs and thereby  reducing 
autoantibody  producti on to some degree [4]. However, PBs and long -lived plasma cells are not 
suscept ible to these therapies [5-7] . Similarly, the available broadly acting immunosuppressant 
agents (eg, azathioprine, cy clophosphamide, and myc opheno late mofetil) and high -dose steroi ds 
do not specifically target plasma cells and PBs, and their utilit y is further limit ed because of 
tolerabilit y issues. 
CD38 i s a ty pe II glycoprotein that is highly  and uniformly  expressed on ant ibody -
producing PB s 
and plasma cells [8], making it a potential target for treatm ent of SLE. In an ex vivo study o f CD38 
expressio n on var ious immune cells in peripheral  blood mononuclear cel ls from pat ients with SLE, 
the highest CD38 expressio n was observed on plasma cells and PBs, followed by natural killer 
(NK) cells, plasmacyto id dendrit ic cells ,a regul atory  T cell subpopulat ion, and naïve T cells [9]. 
The significant ly higher CD38 expres sion on PCs and PBs co mpared with other immune cells 
suggests the potential for select ively depleting these cells with an ant i-CD38 ant ibody . Consistent 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 21of 110
Protocol Incorporating Amendment No 01 19 February 2019
with this hypothesis, daratumumab, a commercially available CD38 antibody  licensed for 
treatm ent of m ultiple myelo ma, effect ively depleted plasma cells and PBs in peripheral blood 
mononuclear cells fro m patients wi th SLE in a dose -dependent manner in vitro [9]. 
Other studi es have confirmed that the levels of CD38 -expressing PBs are increased in pat ients 
with SLE. A study  that transcri ptionally pro filed blood samples from 158 pediatric SLE patients 
ident ified 13 dist inct signatures (ie, phenotypes) of lupus, out of which the PB signature with 
elevated expressio n of CD38 and increased levels of anti-dsDNA, antibodies was most strongly 
positively correlated with disease activit y [10]. These findings were supported by a study o f 
immunophenoty ping of 143 pati ents wi th SLE [11]and are consistent with previous studies in 
patients wi th SLE treated wi th rituximab that showed a positive correl ation between disease 
progression and the level of CD38- expressing PBs that are not susceptible to the ant i-CD20 
antibody  [12]. 
Thus, the level o f unmet need in SLE remains high, and therapies with novel mechanisms o f action 
are needed to provide improved efficacy in reducing disease act ivity, to hel p decr ease use o f 
corticosteroi ds, and to improve qualit y of life for patients with SLE. Specifically, targeted 
therapi es that deplete PBs and plasma cells could be of important therapeutic benefit for patients 
with SLE. 
Rationale for Proposed Study 4.2
TAK -079 i s,a fully human IgG1 monoclonal ant ibody  (mAb) that binds with high affinit y to 
CD38. The available nonclinical and clinical data demonstrate an acceptable safet y profile and 
encouraging pharmacodynamic (PD) effects in reducing target cells expressing CD38. Therefore, 
TAK -079 i s being proposed as a potential treatment for moderate to severe SLE in adult patients.
Preclinical studies showed that TAK -079 depl etes the CD38 -expressing target cells by means of 
antibody -dependent cell -mediated cy totoxi city and com plement -dependent cytotoxicit y 
(TAK -079-10012). In in vitro experiments, the addit ion to TAK -079 to bl ood or bone marrow 
samples taken from pat ients with lupus was shown to depl ete 80% of pl asma cell popul ations, 
including short -lived plasma cells (CD19 + plasma cells) and long -lived plasma cells (CD19-
plasma cells). Addit ionally, the number of cells producing autoantigen -specific antibodies was 
dram atically reduced, including VH4 -34 9G4+ antibodies (70% reduction), anti -Ro ant ibody  
(70% reducti on), and ant i-dsDNA ant ibody  (80% reducti on) [13].
In vivo, the efficiency o f deplet ion of each cell t ype correlated with the levels of CD38 expressio n 
and exposure of TAK -079 in healt hy cyno molgus mo nkeys (TAK -079-10015, TAK -079-10018, 
TAK -079-1001 9). Furthermore, TAK -079 dem onstrated anti -inflammatory  and 
disease -modifying act ivity in a m onkey m odel of collagen -induced arthrit is (CIA) that mirrors 
clinical aspects of human rheumatoid arthritis (RA) (TAK -079-10032) .TAK -079 treatm ent 
prevented or re duced jo int inflammat ion and subsequent jo int, bone, and cartilage damage with 
efficacy co mparable to high -dose dexamethasone but with better tolerabilit y (as measured by  
changes in body  weight). Thi s efficacy correlated with the reduction of B, NK, and T cells in 
peripheral  blood. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 22of 110
Protocol Incorporating Amendment No 01 19 February 2019
To date, TAK -079 has been evaluated in a single escalat ing-dose study of healt hy subjects (n =74; 
TAK -079-101). In that study , TAK -079 administratio n resulted in dose -dependent, reversible 
reducti on of  blood cell  subsets that e xpress CD38, including NK cells, PBs, B cells, and T cells. 
TAK -079 was well tol erated, wi th no unexpected and unwanted clinical or hematologic effects 
ident ified.
In conclusio n, the available nonclinical and clinical data demonstrate an acceptable safety profile, 
and encouraging PD effects in reducing target cells expressing CD38. These findings suggest that 
TAK -079 m ay have the potenti al to address the unmet needs of SLE.
The primary  object ive of the TAK -079 SLE development program is to invest igate the utilit y of 
TAK -079 as a disease -modifying therapy in SLE. This phase 1b double -blind, placebo -controlled, 
multicenter study will evaluate the safet y, tolerabili ty, pharmacokinet ics (PK), and PD of 
TAK -079 in pati ents wi th moderate to severe SLE by  com parin g act ive TAK -079 wi th matching 
placebo in combinat ion with standard background therapy  for SLE. 
Rationale for Study Design, Dose, and Endpoints 4.3
4.3.1 Rationale of Study Design 
This phase 1b study  is desi gned to further understand the proof of mechanism and potenti al 
biologic activit y of TAK -079 in a study  popul ation with specific, m easurable clinical 
manifestations of SLE. The study  design allows for patients to continue their SLE background 
therapy , managed under the care of their physician, while evaluat ing the benefit -risk of TAK -079 
as an invest igational add -on therapy .
Sequent ially enrolling the double -blind cohorts allows for the evaluat ion of TAK- 079 dosing in a 
step-wise, double -blinded design, thereby providing for both an intracohort and cross -cohort 
analysis of act ive TAK -079 and m atching placebo (see Figure 2.a).
Takeda clinicians conduct reviews of adverse events (AEs), serious adverse events ( SAEs), and 
related clinical parameters to ensure consistency wit h an acceptable benefit -risk rati o throughout 
the study . At the pati ent level , safet y and tol erability  are cl osely  monitored f or each pati ent at the 
completion of each dose and before the next subsequent dose to ensure clinical dosing criteria are 
met before each subsequent administration of TAK -079 or m atching placebo. Further, safet y is 
assessed at the end of treatment in each cohort, which allows for decisio ns regarding enro llment in 
subsequ ent cohorts. A 12 -week post -dose safet y follow-up peri od allows for continued 
observat ion and assessment of safet y and sustainabilit yof biologic activi ty. Pati ents whose safet y 
param eters do not return to adequate protocol -defined rebound levels by the en d of the safet y 
follow-up peri od m ay progress to a l ong-term follow-up peri od for continued mo nitoring ( Table 
3
.b, Table 6.b ). These cont inued safet y observat ion peri ods provi de optimal oversight and 
assessment of any ongo ing study -related sequel a.
4.3.2 Rationale for Selected Patient Population
As outlined in inclusio n criteria (Sect ion7.1), the study populat ion is limited to patients with SLE 
who exhibit moderate to severe disease wit h persistent disease activit y and who have not
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 23of 110
Protocol Incorporating Amendment No 01 19 February 2019
responded adequately to standard SLE background therapy treatment but have not recent ly had an 
acute flare that was moderate to severe in nature. All patients must be posit ive for anti -dsDNA 
antibodies and/or antiextractable nuclear antigens (ant i-ENA) antibodies. 
Based on findings fro m the first -in-human (FIH) study  (TAK -079- 101), most subj ects will have 
detectable expressio n of CD38. The level o f CD38 expressio n (quantified in mo lecules of 
equivalent soluble fluorochrome [MESF]) on PB cells was evaluate d from samples obtained at 
screening in the TAK -079- 101 study  in healt hy subjects. A total of 129 evaluable subjects were 
analyzed for expression of CD38, of who m 100% had detectable levels of CD38. The level o f 
CD38 expressio n in these healt hy subjects ra nged approximately 5 -fold fro m 693,474 MESF units 
to 3,531,222 MESF units, with a mean o f 1,747,840 MESF units. The lowest CD38 expressio n 
was approximately 7- fold higher than background, indicating that healt hy subjects express high 
levels o f CD38 on the surface of peripheral blood PBs (Supplemental Study  Report, Baseline 
CD38 Expressio n in Healt hy Subjects fro m the TAK -
079-101 Study , is available on request).
4.3.3 Rationale for Dose 
The study  dosing regimen consists of a single subcutaneous (SC) inject ion of either TAK -079 or 
matching placebo, administered every  21days (ie, 3 weeks) over the course of a 12- week dosing 
period for a m aximum  of 4study doses, in combination with a principal invest igator –
directed 
background therapy  for SLE.
The select ion of doses and the frequency of administration of TAK- 079 are based on a 
comprehensive review and analysis of data derived from the following: (1) dosing of healthy 
subjects wi th TAK -079 (Study  TAK -079- 101); (2) nonclinical repeat TAK -079 dosing studi es 
(TAK -
079-100
15, TAK -079- 1018, and TAK - 079-10019) in cyno molgus monkeys; and (3) data 
derived fro m repeat dosing of daratumumab (Darzalex), a related anti -CD38 cy tolytic ant ibody  
that is licensed for treatment in mult iple myelo ma [11]. 
The starting dose of 45 mg for the init ial dosing cohort (ie, Cohort A) is selected based on the 
favorable safet y profile and PD target effect (ie, a sustained reduction of PBs) observed after a 0.6 
mg/kg dose was administered to healthy subjects (Study  TAK -079- 101). A single SC dose of 0.6 
mg/kg TAK -079 reduced the level o f PBs in peripheral blood >90% and NK cells >80% without 
comparable reductions in mo nocy tes and B and T cells. Levels of PBs and NK cells recovered to 
50% of baseline levels 21 days after administration, on average. At this dose, there were no SAEs, 
on-study  deaths, or AEs that led to study  discontinuation. No remarkable findings for laboratory  
tests, el ectrocardi ogram  (ECGs), vi tal signs, or physical examinat ions were reported that were 
related to TAK -079 administration. Two subsequent dosing cohorts are planned at doses of 90 mg 
(2-fold increase from the first dose cohort) and 135 mg (a 50% increase from the previous cohort). 
Because patients with lupus generally exhibit higher levels of PBs expressing CD38 than those 
seen in healt hy study  subjects, hi gher doses m ay be needed to achiev e com parable PD effects; 
subjects should be carefully  monitored to m aintain a balance of benefit -risk (refer to the 
dose-modeling overview shown in Figure 4, provided in Appendix G).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 25of 110
Protocol Incorporating Amendment No 01 19 February 2019
criteria). Preliminary data show antimyelo ma act ivity with minimal toxi city at a dose of 45 m g 
after 4 weekly  doses.
The expected potential benefits of TAK -079 in patients wi th SLE are based on the observed 
non-clinical and clinic al PD effects, as described in detail in the investigator’s brochure. Quite 
relevant to thi s study , the therapeutic efficacy  of TAK -079 was demo nstrated in a monkey 
collagen -induced arthrit is model, which mirrors clinical aspects of human RA. TAK -079 
treatment reduced jo int inflammation and subsequent jo int, bone, and cartilage damage. It had 
comparable efficacy  to the steroi d dexamethasone, as evidenced by  reduct ion of arthrit is scores 
and faster reduction of C -react ive protein levels. This efficacy correl ated wi th the reduction of B, 
NK, and T cells in peripheral blood. Furthermore, TAK- 079 was better tolerated than 
dexamethasone; no weight loss was observed in animals treated with TAK -079, in contrast to 
those treated with dexamethasone (TAK-079- 10032).
In the FIH study  (TAK -079- 101), a single dose of TAK -079 IV or SC treatment resulted in the 
transi ent, dose -dependent, reversible reduct ion of blood cell subsets that express CD38, including 
NK cells, PBs, B cells, and T cells. Alt hough the duration of PB d epletion was relatively 
short -lived (up to 15 days in SC cohorts) after a single administration at low doses, this study 
demonstrated that PBs are particularly sensit ive to TAK -079 as woul d be expected, based on the 
target of this mAb and the high expressi on of CD38 on PBs.
In conclusio n, considering the efficacy signals fo llowing administration of TAK -079 in a monkey 
collagen -induced arthritis model, and the promising PD effects fo llowing TAK -079 administration 
observed in both in vitro and in vivo studies , as well as in the FIH study in healt hy subjects, further 
investigat ion of TAK -079 as a potential treatment for SLE is warranted. Patients with SLE have a 
PB (CD38- expressing) phenotype, therefore an agent such as TAK -079 that specifically  targets 
CD38 -expressing cells may  have potenti al benefi t for pati ents wi th SLE.
Possible AEs are based on the intrinsic pharmaco logy of TAK -079, reports from other bio logic 
agents, the nonclinical data to date, and the limited data from Study  TAK -
079-101 in healt hy 
human subjects. Risks of TAK -079 may include, but are not limited to, the following: ISRs, CRS, 
changes in hematologic parameters, and infect ions. Patients will be monitored closely for these 
and other potential side effects in accordance to the assessments and procedures outlined in this 
protocol  (see Secti ons 6.4, 6.5,
 and 9.0). Further details on TAK -079 ri sks can be found in the 
TAK -079 Invest igator’s Brochure.
In the FIH trial (Study  TAK -079- 101), single doses of TAK -079 ranging from 0.0003 to 0.06 
mg/kg given by IV infusio
n and 0.03 to 0.6 mg/kg given by SC inject ion were well tolerated. AEs 
were mild to moderate in intensit y, wi th most AEs being mild. There were no SAEs or deaths 
reported in the study , and no AEs l ed to ei ther study  or visi t discontinuat ion. No remarkable 
findings f or laboratory  tests, ECGs, vital signs, or physical examinat ions were reported that were 
related to TAK -079 treatm ent (TAK -079- 101 CSR ).
Mild, transient CRS was observed in subjects who were administered higher TAK -079 doses, 
mostly in the 2 cohorts receiv ing higher intravenous doses. Commo n symptom s included fever, 
headache, dizziness, and orthostatic hypotensio n. Incidences of CRS co incided with moderate 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 26of 110
Protocol Incorporating Amendment No 01 19 February 2019
cytokine increases and occurred in the same cohorts that significant and rapid lymphocy te 
depletion occurred, suggesting that the symptoms associated with CRS could have been caused by 
lymphocy te depl etion rather than act ivation. These data are consistent with findings fro m 
nonclinical studies that showed that TAK -079 i s a cell -deplet ing antibody and did not elicit 
cytokine release fro m viable leukocytes. Relative to the intravenously dosed study groups, the 
subcutaneously dosed study  groups had fewer subjects who experienced CRS, and there were 
minimal cytokine level increases despite subjects receiving TA K-079 at doses 10 -fold higher than 
the intravenously dosed study  groups. Thi s coul d be the result of differences in the kinetics of the 
drug. However, SC administration effectively depleted PB for a longer duration than seen wit h IV 
administration, suggest ing SC administration is a suitable route of administration for future 
clinical development. In addit ion, only  mild, transient ISRs were observed after SC inject ions, 
most of which reso lved within 7 days. The ISRs have an inverse dose -effect relationship, as 5 out 
of 6 subjects administered the lowest SC dose had ISRs, whereas only one subject had a mild ISR 
in each of the 2 highest dose cohorts.
Benefits and Risks Conclusions 4.5
Because of the limited clinical exposure of TAK -079, the overall clinical benefi ts and risks of 
TAK -079 have not been fully determined.
Risks of TAK- 079 may  include, but are not limited to, the following: ISRs, CRS, hypersensit ivity 
reacti ons, changes in hematologic parameters, and infect ions. These AEs are based on the intrinsic 
pharmaco logy of TAK -079, reports from other biologic agents, the nonclinical data to date, and 
the limited data fro m Study  TAK -079-101 in healthy human subjects. Patients will be mo nitored 
closely  for these AEs in clinical studies with TAK -079.
Potenti al benefits of TAK -079 in patients with SLE are based on nonclinical and clinical PD 
effects. Patients with SLE have a PB (CD38 -expressing) phenoty pe; therefore, an agent such as 
TAK 079 that specifically  targets CD38 -expressing cells may have potential benefit fo r pati ents 
with SLE.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 29of 110
Protocol Incorporating Amendment No 01 19 February 2019
6.0 STUDY DESIGN AND DES CRIPTION
This phase 1b double -blind, pl acebo -controlled, mult icenter study will evaluate the safet y, PK, 
and PD of TAK -079 in a study  popul ation receiving standar d principal invest igator –directed 
background therapy  for m oderate to severe SLE . 
Study Design 6.1
The study will co mpare active TAK -079 with matching placebo in combinat ion with a background 
SLE standard treatment, across 3 sequent ially enrolling cohorts in a doubl e-blinded study  design. 
A 3:1 rando mizat ion, within each cohort, will assign each patient to: (1) TAK -079 administered as 
a single SC inject ion every 3 weeks for 12 weeks (total o f 4 doses); or, (2) matching placebo given 
in same route and schedule (see Figure 2.a). Each cohort will enroll 8 patients; 6 patients will be 
rando mized to TAK- 079 dosing and 2 patients to TAK -079 m atching pl acebo. After each dosing 
day, pati ents will  return for postdose assessments as outlined in Table 3.aand Table 3.b.
Following complet ion of the 12 -week dosing period, patients will return for an addit ional 12-week 
safet y follow-up peri od, com pleting safet y visits every 4 weeks and ending this postdosing study  
period wi th a safet y visit on Week 24. Based on clinical assessments at this visit, patients may 
complete the study or may advance to the l ong-term safet y follow-up peri od, for an addi tional 
on-study  12-week safety  monitoring peri od (based on end -of-study  criteria outlined in Table 9.c), 
during which t ime the end of study parameters not met and deemed by the principal investigator as 
study  related, will continue to be assessed and fo llowed as outlined in Sect ion9.4. 
Study Drug 6.2
Study  drug is to be administered only  to eligible pati ents under the s upervisio n of the principal 
investigator or ident ified subinvest igator(s). Patients will be dosed TAK -079 or matching placebo 
in accordance to their assigned study  cohort every  3 weeks, as outlined in Table 6.a. All 
protocol -specific cri teria for administrati on of  study  drug must be m et and documented before 
drug administration (see Table 6.b. During the study, dosing of TAK -079 may be temporarily held 
or discont inued, based on the dosing criteria outlined in Table 6.bor in accordance to the principa l 
investigator’s judgment. Dosing of TAK -079 m ay not otherwise be reduced or escalated for any  
given pat ient (study  dosing by cohort, will be assessed and sequentially increased, as outlined in 
Figure 2.a). 
Concomitant medicat ion, to include acceptable criteria for principal invest igator -directed SLE 
background medicat ions, are provided in Sect ion9.2.3 .
 Rescue therapy  inform ation is outlined in 
Secti on6.2.4.
In accordance with t imings and criteria outlined in Section 6.3.1 key safet y data will be reviewed 
and evaluated by Takeda clinicians/designees, who will review the safety of all treated patients and 
make decisio ns regarding dose escalation. In addit ion, ch anges to the dose -escalat ion scheme or 
dose schedule (dosing interval) may be considered. All decisio ns will be documented in writ ing. 
Any decisio n to m odify the dose -escalat ion scheme and schedule (with the except ion of testing 
intermediate dose levels, o r expanding a dose level) will be communicated to institutional review 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 30of 110
Protocol Incorporating Amendment No 01 19 February 2019
boards (IRBs). The investigators will also be informed in writ ing o f the more conservat ive 
approach. The protocol will be considered for amendment accordingly. 
Table 6.a TAK -079 Dosing by Study Cohort
Study Dosing Arms
CohortTAK -079 aMatching Placebo a
Patients
(n)Dose
(mg)Patients
(n)Dose
(mg)
Cohort A 6 45 2 NA
Cohort B 6 90 2 NA
Cohort C 6 135 2 NA
Abbreviations: NA, not applicable.
aPatients will receive TAK -079 or matching placebo through SC administration every 21 days (ie, 3 weeks) over the 
course of 12 weeks, for 4 total doses.
6.2.1 Premedication
On each dosing day , 1 to 3 hours before TAK- 079 administrati on, pati ents are to be premedicated 
with a regimen consistent with, but not limited to, the follo wing:
Antipyretic: oral acetaminophen (650 to 1000 mg). 1.
Antihistamine: oral or IV diphenhydramine (25 to 50 mg, or equivalent). 2.
The clinical site is responsible for sourci ng premedicat ions outlined in the protocol.
6.2.2 Post-dose Medications
Patients m ay receive l ow-dose m ethylpredniso lone (<20 mg) for the prevent ion of delayed 
inject ion-related reacti on, as clinically indicated, and under the discret ion of the principal 
investi gator.
NOTE: Pati ents wi th a higher risk of respiratory  com plicat ions (eg, patients with a history  of 
chronic obstructive pulmo nary disease [COPD] and patients with asthma) may be administered the 
following, after each study  dose (at the invest igator’s dis cretion):
a)An ant ihistamine (diphenhydramine or equivalent) on the first and second days after study 
dosing.
b)A short -acting β2 -adrenergic receptor agonist, such as salbutamo l (albuterol) aerosol .
c)Control  medicati ons f or lung disease, such as the following: 
–Inhaled corticosteroids wit h or without long -acting β2 adrenergic receptor agonists for 
patients wi th asthma. 
–Long -acting bronchodilators, such as tiotropium or salmeterol with or without inhaled 
corticosteroi ds, for pati ents wi th COPD.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 31of 110
Protocol Incorporating Amendment No 01 19 February 2019
The clinical site is responsible for sourcing treatments administered pre -or post -TAK -079 
inject ion, as outlined in the protocol.
Based on emerging data, the Takeda phy sician/designee may  enhance treatm ents administered 
pre-or post -TAK -079 inject ion to ensure patient saf ety.
6.2.3 TAK -079 and Matching Placebo Administration
The strength of the TAK -079 drug product for SC use in this study  is 100 m g TAK -079 in 1 mL 
(100 m g/mL). 
After patients have received premedicat ion treatment, the TAK -079 dose or matching placebo will 
be ad ministered with a syringe as SC inject ions up to a maximum vo lume of 2 mL, such that the 
full schedule dose has been administered. The time and anatomical site o f SC inject ion must be 
recorded for each dose, with the site of inject ion rotated for each dose (inject ion sites of the 
abdo men, thi ghs, arms, and upper buttock area are acceptable). Refer to the pharmacy manual for 
detailed instructions regarding preparation of TAK -079 and matching placebo dose. 
6.2.4 Rescue Therapy
Rescue therapy  is defined as addit ional dosing of concomitant medicat ions in accordance with 
institutional pract ices or the physician’s best medical judgment to control and manage underlying 
SLE condit ions. Protocol -restricted and dose -limit ed concomitant medications are outlined in 
Table 7.aand Table 7.b(Note: Concomitant dosing of cy clophosphamide is restricted during study 
enrollment).
Patients shoul d remain on their stable dose of immunosuppressive and corticosteroid therapies 
throughout the study  (as aligned wit h protocol requirements in Table 7.aand Table 7.b) . 
Decreases in the dose of immunosuppressants, due to toxicit y, are al lowed at the di screti on of  
the invest igator. 
Increasing, adding, or changing background immunosuppressive, or adding a medicat ion not 
otherwi se wi thin protocol limits, as deemed necessary  by the principal invest igator to treat 
manifestations of SLE, must resul t in discont inuat ion of the patient fro m study  dosing and 
advancement to safet y follow-up; these patients will be categorized as study  nonresponders.
NOTE: Pati ents who requi re an increase in corticosteroid dose above 0.5 mg/kg/d (or 40 mg/d of 
predni sone) or equivalent, for control of SLE activit y, or m anagement of a new SLE flare during 
the study , are to be discont inued fro m study  drug. The prednisone dosage or equivalent may be 
increased to a dose that is less than or equal to 0.5 mg/kg/d or 40 mg/d , whichever is lower. 
However, dosing should be tapered to the preflare level or 20 mg/d, whichever is greater, within 4 
weeks or less. If tapering is not possible AND a higher dose is needed to treat SLE manifestations, 
the pati ent m ust be discont inued fr om study  drug and advanced to safety  follow
-up, and be 
designated a study  nonresponder. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 32of 110
Protocol Incorporating Amendment No 01 19 February 2019
Study Stopping Rules 6.3
Takeda clinicians/designee will provide ongo ing safet y oversight and surveillance throughout the 
study dosing peri od and safety  follow-up peri ods. As such, TAK -079 clinicians are to receive and 
trend all reported SAEs and conduct a review of all safet y data peri odically  throughout the study . 
Based on outcomes of the Takeda safet y reviews and in accordance with predefined criteria, 
decisio ns about the dosing regimen are to be made and implemented.
6.3.1 Assessment and Criteria for Terminating Patient Dosing
Before each study  dose, principal invest igators provide the medical mo nitor (MM) wi th a 
summary of assessment outcomes associated with the dosing criter ia, for review and approval. In 
instances where clinical parameters do not meet dosing criteria, study dosing must be temporarily 
withheld unt il parameters meet dosing levels or discontinued, as outlined in Table 6.b. As such, 
patients shoul d return for re -evaluat ion of dosing criteria every 3 weeks unt il completion of Week 
12 of the dosing period, at which t ime the patient begins the safet y follow-up peri od.
In addit ion, study  drug must be permanently discont inued, and pat ients must advance to the safet y 
follow-up peri od of  the study , if any of the foll owing is experi enced: 
An AE or other medical condit ion in which the principal investigator deems it is not in the bes t 
interest of the patient to continue study  dosing. 
The pati ent chooses to wi thdrawal  from study  dosing.
The pati ent has a confirmed pregnancy .
NOTE : If two or more patients discont inue study drug dosing based on the dose discont inuat ion 
criteria in Table 6.b, the Takeda clinician/designee will review available safet y data, to determine 
if adjustments to the treatment plan should be made. In such instances, discont inued pat ients will 
need to be unblinded to assess relatedness to the study drug. The unblinding process is outlined in 
Secti on 8.1.5.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 33of 110
Protocol Incorporating Amendment No 01 19 February 2019
Table 6.b Summary of Dosing Criteria
Safety ParameterDosing Criteria
Continue Dosing Dose Hold aDose Discontinuation b
Laboratory Investigations
Neutrophils ANC ≥1500/mm3Total neutrophils ≥Grade 2 c
ANC <1500/mm3
Platelets Thrombocytopenia ≤Grade 2
Platelets ≥50,000/mm3Thrombocytopenia ≥Grade 3 c
Platelets <50,000/mm3
T cells T cells ≥500 cells/uL 
NOTE: Dosing may continue in 
instances of T cells < 500 cells/uL 
if CD3+ cell count is ≥70% of the 
baseline levelCD3+ cells count <500 cells/uL and
is < 70% of baseline CD3+ cell 
count level.
Hgb ≥8 g/dL <8 g/dL
IgG, IgA, IgM levels >50% LLN ≤50% LLN 
Events of Clinical Interest
TAK -079–related infusion reaction (to include systemic 
signs and symptoms related to CRS d)
NOTE : IRR is classified in accordance to the NCI 
CTCAE criteria, version 4.03. CRS is classified in 
accordance to the parameters outlined in Appendix B
andAppendix C.≤Grade 1 with symptomatic 
treatment allowed in accordance 
with Appendix C.
NOTE: Dosing may resume after 
symptoms have resolvedf. ≥Grade 2 IRR 
orCRS fleading to moderate clinical 
symptoms based on a global assessment of 
symptoms
Hypersensitivity (allergic reaction or anaphylaxis) e≤Grade 2
In accordance with NCI CTCAE, 
version 4.03 grading for allergic 
reactions which respond pro mptly  
to symptomatic measures≥Grade 3 c
In accordance with NCI CTCAE (version 
4.03) grading for allergic reaction
orany signs or symptoms of an anaphylactic 
reaction [14]
Systemic infection Grade 2 c 
Hold dosing until the infection is 
resolved≥Grade 3c
orinfections requiring hospitaliz ation 
Abbreviations: ANC, absolute neutrophil count; CRS, cytokine release syndrome; NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; Hgb, 
hemoglobin; IRR, infusion -related reaction ; LLN, lower limit of normal. 
aPatients whose clinical parameters meet dose -hold criteria, will not receive their next scheduled cohort dose (ie, TAK -079 or matching placebo), and instead return for the next 
scheduled dose -criteria assessment for reassessment and evaluation of the subs equent dosing.
bPatients whose clinical parameters meet dose discontinuation criteria are to be permanently discontinued from study dosing (i e, TAK -079 or matching placebo); patients are to then 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 34of 110
Protocol Incorporating Amendment No 01 19 February 2019
advance to the safety follow -up period of the study, complet ing all associated assessments, while continuing to receive standard background therapy for SLE, in accordance to 
principal investigator’s discretion and local institutional practices.
cLaboratory grading, allergic reactions, and infection grading is base d on NCI CTCAE v4.03.
d Afull cytokine panel is to be obtained for any suspected events, at any grade, of CRS; refer to Section 6.5.2 for further i nformation and suggested management of CRS. 
e See Section 6.5.1 for further information regarding study -related hypersensitivity reactions. 
f See Appendix Band Appendix Cfor further detai ls on the grading and clinical signs and symptoms of CRS.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 35of 110
Protocol Incorporating Amendment No 01 19 February 2019
6.3.2 Assessment and Criteria for Terminating Cohort Advancement
A cohort analysis, assessing for safet y trends and potential risks associated within and across 
dosing cohorts will be conducted near the completion of each cohort. The Takeda 
clinicians/designee will take into consideration all SAEs and AEs of severe intensit y medically 
considered related to study  drug in dose escalat ion decisio ns. Analysis for each cohort will be 
initiated at the time the seventh pat ient within each study  cohort com pletes all fo llow -up 
assessments and procedures associated wit h their second study dose. Decisio ns regarding cohort 
advancement will be made once the cohort completes full enro llment, incorporating full 
assessment of safet y parameters of all pat ients in the cohort. 
Based on these findings, and in alignment with prot ocol-defined dose hold and dose 
discontinuat ion criteria, the study  may: (1) advance enrollment to the next cohort at the next 
protocol -defined dose l evel, (2) advance enrollment in the next cohort at a reduced intermediate 
dose l evel, (3) expand enrollmen t at the current dose level, or (4) enact early terminat ion of the 
study .
Precautions and Restrictions 6.4
Patients shoul d be cl osely  monitored both before and for at l east 4 hours after each dose, with 
additional assessment and observat ions as necessary based on the principal investigator’s best 
medical judgment, and as warranted by exhibited clinical signs or symptoms at each study  clinic 
visit. Postdose monitoring should include vital sign assessments as outlined in Section 9.2.5, and 
additional postdose m edicat ions for those wi th a history  of asthma or COPD, as outlined in 
Secti on6.2.2.
6.4.1 Pregnancy and Lactation
TAK -079 has not been administered to women who are pregnant or lactating. Dedicated fertilit y 
and embryo -fetal devel opment toxi cology studi es have not been conducted with TAK -079. 
However, there were no TAK -079–related changes in organ weights or microscopic findings noted 
in the male and female reproductive tract of monkeys fo llowing administration for up to 13 weeks. 
Women of child-bearing potential may be enro lled in clinical trials wit happropri ate precautions to 
prevent pregnancy  (addi tional details in Secti on9.2.9).
TAK -079 shoul d not be administered to women who are pregnant or breastfeeding.
6.4.2 Drug Interactions
Nonclinical drug interaction studies have not been conducted with TAK -079. However, as a fully 
human IgG1 mAb, the ri sk of drug -drug interactions is low.
6.4.3 Interference with Serological Testing
Anti-CD38 m onocl onal antibodi es have been reported to bind to CD38 on red blood cells 
(RBCs) and results in a posit ive indirect coombs test, which may persist for up to 6 months. The 
determinat ion of a patient’s ABO and Rh blood type are not impacted, but the RBC binding may 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 36of 110
Protocol Incorporating Amendment No 01 19 February 2019
mask detec tion of  antibodi es to minor ant igens in the pat ient’s serum [14,15].It is possible 
TAK -079 m ay affect the resul ts of these bl ood tests, this is being evaluated. Until those tests are 
known, i t is recommended that baseline ty pe and serol ogical screening be established before 
starting TAK -079. Pati ents should keep these results in case future transfusio ns are needed. Blood 
transfusio n centers should also be informed o f this interference wi th serol ogical testing as 
necessary . 
Manag ement of Events of Clinical Interest 6.5
6.5.1 Hypersensitivity Reactions: Infusion and Injection Site Reactions
Since infusion react ions and other ant ibody -mediated hypersensit ivity react ions have been 
reported with other bio logic agents, similar AEs may  be seen wi th TAK -079. Infusio n react ions 
are poten tially dose -limit ing AEs, not uncommo nly associ ated wi th IV administrati on of  biologic 
agents, but are less frequent ly associated with SC inject ion of these therapies [16-19].
Symptom s of hypersensit ivity may range from mild skin rash to more severe reactions, wheezing, 
hypotension, poor perfusio n, respiratory  arrest, and rarely death. Nonanaphylactic clinical 
hyper sensi tivity typically occurs within the first hour; however, delayed responses have been 
reported in literature. Symptoms of anaphylaxis, a potentially life -threatening condit ion, range 
from swelling, angioedema, bronchospasm, respiratory  distress, and sho ck [20]. Hypersensit ivity 
reacti ons in the literature often occur within a few hours fo llowing drug intake. Based on outcom es 
from studi es wi th daratum umab, pati ents wi th pre-exist ing COPD or asthma may be at particular 
risk for such respiratory  com plicati ons as bronchospasm should an infusion react ion event occur. 
Therefore, patients whose fo rced expiratory  volume in 1 second (FEV 1) is <50% of predi cted 
norm al will be excluded from  study  parti cipat ion (see Section 7.2) [21]. Eligible patients with a 
history  of COPD m ay requi re addi tional postdose medicat ions to manage respiratory  
complicat ions (see Sect ion6.2.2) [18].
To date, subjects administered TAK -079 have not exhibited anaphylact ic symptoms. In the 
clinical study  of healthy subjects (TAK -079-101), an infusio n-related reacti on (IRR) was defined 
as a treatme nt-emergent adverse event (TEAE) occurring wit hin 2 hours of the start of an infusio n; 
there were no IRRs in this study  as no allergic or cy tokine rel ease react ions were observed within 
this time period.
In thi s study :
Patients wi th a history  of severe allergi c or anaphylact ic react ions to recombinant proteins or 
excipients used in the TAK -079 f ormulation are not eligible for this study  and therefore will 
not be exposed to TAK -079. 
Prem edicat ion before each study  dose, to prevent infusio n reactions, is mandatory  for all  
patients (as described in Sect ion6.2.1); postdose medicat ion can be administered at the 
invest igator’s discret ion.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 37of 110
Protocol Incorporating Amendment No 01 19 February 2019
Patients who are treated with TAK -079 will be carefully  monitored in the clinic for 4 hours 
after dosing, and any AE will be managed in accordance with available guidelines or 
institutional standards of care [22,23] . 
NOTE: Addi tional blood pressure (BP) m easure shoul d be assessed at any  time the patient 
complains of symptoms consistent with an infusio n reaction. If the patient experiences 
hypotension (with or without symptoms), intensive blood pressure monitoring according to loc al 
practi ce shoul d be insti tuted. The pati ent shoul d not be rel eased from  the si te unt il blood pressure 
has returned to Grade 1 or baseline for at least 1 hour.
6.5.1.1 Management Recommendations for Hypersensitivity Reactions
Patients in clinical trials receiving TAK -079 are to be carefully mo nitored for signs and symptoms 
of ISRs, wi th appropri ate m edical management of these events. Depending on the severit y of the 
reacti on, m anagement m ay include di scontinuati on of  SC administrati on of  TAK -079 and/or the 
adminis tration of  appropri ate medical therapy.
Reco mmendat ions for the m anagement of hypersensit ivity reacti ons [22], are as fo llows:
Grade 1 
a) S tudy Management :
If the full dose of TAK -079 has not y et been administered, hold dosing unt il 
symptoms resolve, at which time the remainder of TAK -079 dose m ay be 
administered. 
b)Patient Support : 
Moni tor cl osely  until resol ution of symptoms .
Grade 2
a)Study Management :
If the full dose of TAK -079 has not yet been administered, hold dosing unt il 
symptoms resolve, at which time the remainder of TAK -079 dose m ay be 
administered.
b)Patient Support : 
Administer appropriate symptomat ic and prophylactic medical care; 
consider post -inject ion medications as outlined in Section 6.2.2 .
For allergic reaction, provide symptomat ic treatment (e.g. antihist imines, 
nonsteroidal ant i-inflammatory drugs , narcoti cs, epinephrine) as medically 
appropriate and consider post -infection medicat ions (as per Section 6.2.2).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 38of 110
Protocol Incorporating Amendment No 01 19 February 2019
Grade 3 or Greater (symptom atic bronchospasm with or without urticaria, angio edema, 
hypotension). 
a)Study Management : 
Patients are to discontinue study dosing and advance to the safety fo llow-up 
period of  the study .
b)Patient Support : 
Provi de symptom atic treatment, including epinephrine, until symptoms 
resolve. 
Consider hospitalization as appropriate.
Local  inject ion site abnormalit ies have not been observed in mo nkey and rat nonclinical studies 
after SC and/or IV administration of TAK -079. In the clinical study  of heal thy subjects 
(TAK -079- 101), mild inject ion site AEs were reported; mostwere Grade 1 and included primarily 
erythema or tenderness. All inject ion reactions resolved within a few days.
6.5.2 Cytokine Release Syndrome
CRS represents an important infusio n reaction often associated with the use of mo noclonal  
antibodies used in anti -inflammatory and antitumor therapi es. Onset of CRS m ay occur early  in 
therapy , often after the first infusio
n of the drug due to a high level of act ivation of the immune 
system  and engagement and proliferat ion of T cells that can result in increased cytokine release. 
Nonc linical studies have shown that TAK -079 has no agonist activit y, suggest ing that TAK -079 is 
unlikely  to cause cy tokine release due to cell act ivation. There were no TAK -079–rel ated 
increases in cytokines at 0.1 mg/kg. At ≥0.3 mg/kg, dose -related increases (up to 29.5 -fold for any 
individual mo nkey) in tum or necrosis factor alpha (TNF -α) were observed 30 minutes after the 
first dose of TAK -079. These increases were considered small co mpared with elevat ions observed 
during a cy tokine storm  event, were not acc ompanied by  changes in other cy tokines, and di d not 
transl ate into clinical manifestation of an IRR. Increases in serum TNF -α may  be rel ated to 
TAK -079– mediated lyses of CD38+ lymphocy tes.
In the FIH study , conducted in healt hy subjects, rarely  observed sy mptoms consistent with mild 
CRS were reported, particularly at higher doses; dose adjust ment or interruption was not required.
The CRS hallmark is fever. CRS also presents with rash, urticaria, headache, chills, fat igue, 
nausea, and/or vomit ing. [16,17]. S evere CRS is characterized by severe dyspnea, often 
accompanied by bronchospasm and hypoxia, in addit ion to fever, chills, rigors, urticaria, and 
angioedema. The acute respiratory  failure may  be accom panied by such events as pulmo nary 
interstitial infiltra tion or edema visible on a chest x -ray. The syndro me frequent ly manifests within 
1 or 2 hours of init iating the first infusio n. Pati ents wi th a history  of pulm onary insufficiency or 
those wi th pulm onary tumor infil tration may  be at greater ri sk of poor out come and should be 
treated with increased caution [16]. On the basis of outcom es fro m studies of the anti -CD38 mAb 
daratum umab, patients with pre -exist ing COPD or asthma may be at particular risk for respiratory 
complicat ions, such as bronchospasm, should an infusio n reaction or CRS event occur [21]. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 39of 110
Protocol Incorporating Amendment No 01 19 February 2019
Therefore, if the pat ient’s FEV 1is <50% of predicted normal, they will be exc luded fro m study  
participat ion (see Section 7.2). Eligible patients with a history  of COPD may  requi re addi tional 
postinfusio n medicat ions to manage respiratory  complicat ions [18](see Section 6.2.2 )
6.5.2.1 Management Recommendations for CRS
Prem edicat ion before each study dose, to prevent infusio n react ion, is mandatory for all patients as 
described in Section 6.2.1 . Poststudy  dosing medicati on, to be administered at the invest igator’s 
discreti on, is described in Section 6.2.2 . 
Immediate clinical assessment and management of symptoms is key to symptom management. In 
the ant i
-CD38 literature, IRRs are almo st always reported with the first dose [18,24] , therefore 
especially  for the first dose, patients will be monitored in the clinic for at least 4 hours after dosing. 
Medical symptomatic treatment according to guidelines or inst itutional standard of care is 
recommended [17]. Before discharge fro m the clinic, all pat ients will receive informat ion about 
possible signs and symptoms of anaphylact ic reactio ns and CRS to monitor at home. Further, 
patients should receive informat ion about what to do if emergency care is needed (see Appendix B
and Appendix Ctables for further details on clinical signs and symptoms associated with CRS and 
the CRS grading system [17]).
If a pat ient is exhibit ing signs or symptoms possibly assessed as a CRS by the invest igator, a blood 
draw shoul d be perform ed for central  evaluat ion that coul d include, but not limited to, immune 
markers and cytokine markers. Addit ional guidance for study management and patient support for 
CRS, by  grade is as follows: 
Grade 1 (defined as fever, co nstitutional symptoms) 
a)Study Management :Hold study  dosing unt il symptom s reso lve; resume dose of 
TAK -079 at sam e dose l evel after symptom  resol ution.
b)Patient Support: Provi de vigilant supportive symptomat ic treatment, which may include 
antipyretics, anal gesics, and antihistamines (see Appendix C).
Grade 2 (defined as hypotensio n, hypoxia, organ toxicit y) 
a)Study Management: Discont inue study  dosing and advance to safety  follow-up period.
b)Patient Support: Provi de vigilant supportive symptomat ic treatment, which may include 
antipyretics, analgesics, ant ihistamines, with or without tocilizumab. 
Grade 3 (defined as hypotensio n,hypoxia, and severe organ toxicit y) 
a)Study Management: Discont inue study  dosing and advance to safety  follow-up period.
b)Patient Support: Provi de vigilant supportive care, including but not limited to 
tocilizumab, ant ipyretics, analgesics, and antihistamines, as medically indicated [17]. 
6.5.3 Hematologic Effects
Reductions in platelets, lymphocytes, and red blood cells (RBCs) occurred in nonclinical studies in 
some animals administered doses of TAK -079 higher than the no -observed -adverse -effect l evel 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 40of 110
Protocol Incorporating Amendment No 01 19 February 2019
(NOAEL) of 0.3 mg/kg. In the FIH study , no decreases were seen in RBCs or platelets, despite 
observat ions of reducti ons in these cell counts in monkey toxico logy studi es after repeated dosing 
at higher dose levels ( ≥ 1 m g/kg). 
Patients will  be monitored cl osely, including testing of hematology  param eters throughout thi s 
clinical study  as described in Sect ion9.2.8 and Table 9.aand outlined in Table 3.aand  Table 3.b.  
In instances where clinical parameters do not meet dosing criteria, study  dosing m ust be 
temporarily or perm anent ly wit hheld as outlined in Table 6.
b.Medical intervent ions m ay be 
administered according to inst itutional guidelines. 
6.5.4 Infections
In a Good Laboratory  Practi ce (GLP)- compliant 13 -week toxicology  study , bacteri al and/or vi ral 
infect ion, seconda ry to immune suppressio n, was observed in cyno molgus monkeys at IV doses of 
3, 30, and 80 mg/kg administered once every 2 weeks. The NOAEL dose of 0.3 mg/kg, 
administered IV once every week, was not associated with infect ions. In the FIH study , mild 
infect ions, specifically  nasopharyngit is, was reported. 
Patients will be monitored for any signs and symptoms o f infect ions throughout this clinical study 
(see Table 3.
a, Table 3.b, and Table 6.b). In instances where clinical paramet ers do not meet 
dosing criteria, study dosing must be temporarily  or permanent ly withheld as outlined in
 Table 6.b.
Management of infections according to standard med ical care is recommended.
6.5.5 Antidrug Antibody Interactions
Antidrug ant ibody  (ADA) responses were detected in mo st monkeys in the single -dose PK studies 
and the 4- week (non -GLP) and 13- week (GLP) toxico logy studi es. Stronger posit ive ADA 
responses were gener ally associ ated wi th lower serum  concentrati ons of TAK -079, and this was 
especially  notable in the 13 -week repeat -dose toxicit y studi es and at l ower doses. In the 
single
-dose heal thy subject study  (TAK -079- 101), 5 of 54 TAK -079–treated subjects were 
positive for ADA (3 subjects with transient ADA and 2 subjects with persistent ADA). Of these, 
one subject was treated in the 0.06 mg IV cohort and the remaining 4 subjects were treated with 
0.03 m g/kg (2 subjects), 0.1 mg/kg (1 subject), or 0.6 mg/kg (1 subject ) SC TAK -079. 
Immunogenicit y was not associ ated wi th clinically si gnificant AEs, even in the 2 subjects with 
persistent immunogenicit y.
6.5.6 Overdose
As outlined in Sect ion10.2,
 an overdose is defined as a known deliberate or accidental 
administration of invest igational drug, to or by  the study  subject, at a dose above that which was 
assigned to that individual subject (ie, patient) according to the study protocol . 
To date, there is no experience with overdose. If an overdose does occur, as defined in 
Secti on10.2, close monitoring and supportive treatment, as medically required, are recommended. 
Events of overdose, with or without an associated adverse event, should be prompt ly reported to 
the study  MM and will be entered into the electronic case report forms (eCRFs) as an AE.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 41of 110
Protocol Incorporating Amendment No 01 19 February 2019
7.0 SELECTION AND DISCON TINUATION/WITHDRAWAL OF SUBJECTS
The study  popul ation is limited to patients diagnosed with SLE who meet all eligibilit y criteria 
outlined in Sect ions7.1and 7.2.
Inclusion Criteria 7.1
Patients eligible for enrollment in the study  must meet the following criteria: 
The pati ent understands and agr ees to study  parti cipati on by provi ding a signed and dated 1.
written informed consent form (ICF) and any required privacy authorization before the 
initiation of any study procedures (as applicable, the patient’s legally acceptable representative 
may provi de written ICF in accordance to local and regional regulatory  requi rements) and, in 
the opi nion of the invest igator, is capable of co mplying with protocol requirements.
The pati ent is aged 18to75 years, at the time of signing the study  ICF. 2.
The pati ent been diagnosed wi th SLE as defined by  either the 2012 Sy stemic Lupus 3.
International Co llaborating Clinics or the American Co llege of Rheumatology diagnostic 
criteria. 
The pati ent has a SLEDAI -2K score ≥6. 4.
The pati ent is posi tive for anti -dsDNA ant ibodies and/ or anti -ENA ant ibodies. 5.
The pati ent is receiving current concomitant medication that is consistent with medicat ion 6.
restri ctions and limitat ions outlined in Table 7.aand Table 7.b and, in the best medical 
judgment of the principal invest igator, the patient is considered likely to be able to maintain 
dosages consistent with protoc ol limitations throughout the study  dosing peri od, unl ess 
precl uded by  toxicity or the need for protocol -defined rescue therapy .
The pati ent m eets and/or agrees to the fo llowing birth control  requi rements: 7.
a)Men:
Steril e, orif nonsterile, agrees to (1) remain abst inent or(2) use an appropriate method of 
contraception, including a condom with spermicide, from study drug administration on the 
first day  of the first dose until 90 days or 5 half -lives of study  drug, whi chever i s longer, 
after the l ast dose of study  drug administration (see Appendix A). No restri ctions are 
requi red for a vasectomized male patient provided the pat ient is at least 1 year postbilateral 
vasectomy  procedure before study drug administratio n on first day of the fir st dose. A male 
patient whose vasectomy  procedure was performed less than 4 months before study  drug 
administration on the first day  of the first dose m ust fo llow the same restri ctions as a 
nonvasectomized man. Appropriate documentation of surgical procedure should be 
provi ded.
Agrees to not donate sperm fro m study drug administration on the first day of the first dose ,
until 90 days or 5 half -lives of study  drug, whichever is longer, after the l ast dose of study  
drug administration (see Appendix A)
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 42of 110
Protocol Incorporating Amendment No 01 19 February 2019
b)Women: 
Women of child -bearing potenti al: 
–Female pat ients who are of child-bearing p otenti al must agree to remain abst inent or use 
doubl e barri er contracepti on, consist ing of protocol -defined, medically  acceptable 
methods (eg, implants, injectables, oral contraceptives, intrauterine devices). 
Contraception must be used from the time of si gning the ICF through 90 days or 
5half-lives of study  drug, whichever i s longer, after the last dose of study  drug 
administration (see Appendix A).
Women with no child -bearing potenti al will be defined as meet ing at least one of the 
following criteria:
–Postmenopausal (defined as 12 months of spontaneous amenorrhea in wo men with 
serum  follicle-stimulat ing hormone [FSH] levels >40mIU/mL). Appropriate 
docum entati on of  FSH levels is required.
–Surgically sterile by hysterectomy  and/or bilateral  oophorectomy  with appropri ate 
docum entati on of  surgical  procedure.
–Had a tubal ligat ion with appropri ate docum entati on of  surgical  procedure.
–Has a congenital condit ion result ing in no uterus.
Exclusion Criteria 7.2
Patients m eeting any o f the following cri teria are not elig ible for study  enrollment:
1.The pati ent has part icipated in another investigational study within 4 weeks or 5 half-lives of 
study  drug, whichever is the longer, before the screening visit (the 4 -week window is derived 
from the date of the l ast study  procedu re, and/or AE related to the study  procedure in the 
previous study , to the screening visit of the current study ).
2.The pati ent has a posi tive pregnancy test.
3.The pati ent is current ly lactating/nursing or plans to nurse during the study (to include during 
the 12-week safet y follow-up peri od of  the study ).
4.The pati ent has a history  of chronic alcoho l or drug abuse ≤12months before the screening 
visit.
5.The pati ent has a history  of a malignant disease (except for successfully  treated basal  cell 
carcino ma, squam ous cell  carcinom a, or cervi cal carcinom a in situ) ≤5years before the 
screening visit.
6.Patients has COPD or asthma with a FEV 1<50% of predicted normal. 
Note: FEV 1testing is required for patients suspected of having COPD or asthma.
7.The pati ent has had a major surgery  and/or donated or l ost≥1unitofblood (approximately 
500mL) in ≤4weeks before the screening visit.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 43of 110
Protocol Incorporating Amendment No 01 19 February 2019
8.The patient h ad an opportunist ic infect ion≤12weeks before init ial study dosing oris current ly 
undergo ing treatm ent for a chroni c opport unist ic infect ion, such as tuberculosis (TB), 
pneumocyst is pneumonia, cyto megalo virus, herpes simplex virus, herpes zoster, or aty pical  
mycobacteria.
9.The patient currently has, or recently had, an acute or chronic infect ion requiring one or more 
of the fo llowing intervent ions: 
–Hospitalization ≤30days before the screening visit .
–Administered parenteral (IV or intramuscular) ant ibacterial, ant iviral, ant ifungal, or 
antiparasit ic agents ≤30days before the screening visit.
10.The patient has a posit ive T -cell interferon -γ release assay  (TIGRA) (resul ted through Quanti 
FERON TB Gold test or T -Spot/Elispot) at the screening visit (to be analyzed by local 
laboratory ), noting the following: 
a)A purified protein derivat ive (PPD) skin test may be used as a replacement, if TIGRA 
testing is not available.
b)Patients wi th an indeterminate TIGRA result must meet the following criteria: 
–Negative PPD skin test (defined as <5 mm indurat ion).
–Low ri sk of acquiring TB (eg, avoids close contact with TB positive individual[s]), 
and/or chest x -ray ≤6 m onths before the screening visit that is consistent with no 
evidence of latent or active TB).
11.The patient has drug -induced SLE or any other rheumatologic or autoimmune disease 
(excluding secondary Sjögren syndrome or mixed connective ti ssue disease).
12.The patient required therapeut ic intervent ion≤60days before init ial study  dosing for active 
neuropsy chiatri c SLE, as dem onstrated by , but not limi ted to, the following: 
a)New or worsening impaired level of consciousness.
b)Psychosis.
c)Delirium or confusio nal state.
d)Grand mal seizure (including status epilept icus).
e) Asept ic meningit is.
f)Ascending or transverse myelit is.
g)Chorea, cerebellar ataxia, or demyelinat ing syndromes.
13.The patient has an act ive glo merulo nephrit is (ie, a concurrent acute renal flare or documented 
acute renal flare in the previous 3 months that required lupus nephrit is induction therapy) that 
meets at least one of the fo llowing cri teria: 
a)Proteinuria (protein >3000 mg/24 hr).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 44of 110
Protocol Incorporating Amendment No 01 19 February 2019
b)Urine protein- to-creatinine ratio of >300 mg/mmo l.
c)Anestimated glomerular filtration rate (GFR) <30mL/min/1.73m2 (as calculated by  the 
Modificat ion of Diet in Renal Disease [MDRD] formula [see Section 9.2.8.2 ]).
14.The patient has at least one of the f ollowing laboratory  test val ues:
a)Alanine aminotransferase or aspartate aminotransferase >3times the upper limit of norma l 
(ULN).
b)Total  bilirubin >1.5 times ULN (Note: Pati ents wi th a confirmed di agnosis of Gilbert 
syndro me that is documented in the patient’s medical record are not excluded based on this 
criterion).
c)Platelets<75,000/mm3.
d)Neutrophils <1500/mm3.
e)Hem oglobin <8g/dL.
f)IgGless than l ower limit of normal (LLN).
15.The patient has a posit ive test r esult for hepatit is Bsurface ant igen or hepatit isC ant ibody , or 
HIV antibody /antigen, at screening. 
16.The patient has a concurrent m edical condit ion that, in the opinio n of the invest igator, could 
confound interpretation of results or affect the patient’s ability to fully participate in the study.
17.The patient hasa history of severe allergic or anaphylact ic react ions to recombinant proteins or 
excipients used in the TAK- 079 f ormulation.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 45of 110
Protocol Incorporating Amendment No 01 19 February 2019
Excluded and Dose -Limited Medications 7.3
Excluded and dose -limited conco mitant m edicat ions are provided in Table 7.aand Table 7.b.
Table 7.a Excluded Medications
Category or AgentExclusion Criteria
(Exclusion Criteria Must Be Upheld Throughout Study Participation, in 
Addition to the Timepoints Indicated Below) a
Belimumab, abatacept, or 
tocilizumab≤3months before the screening visit
Cyclophosphamide Restricted from ≤12weeks before initiation of on -study dosing
Immunosuppressant 
regimenTo include calcineurin -inhibitors (eg, systemic cyclosporine and tacrolimus), 
leflunomide, to be excluded throu ghout study participation. Must be discontinued at 
least 3 months before screening visit.
Live vaccines All vaccines : Maintain restrictions as follows and throughout study participation, 
until 12 weeks following the last dose of study dosing
Live vaccines : 90 days before initial dosing on study Day 1
Inactivated vaccines : 30 days before initial dosing on study Day 1 
Rituximab or other cell 
depleting biological agents≤6months before the screening visit 
Alemtuzumab No previous or concurrent dosing whi le on study
Abbreviation: AE, adverse event. 
aExceptions to excluded medications may be allowed for treatment of adverse events, after discussion and agreement 
between the sponsor and principal investigator.
Table 7.b Dose -Limited Concomitant Medications
MedicationsDosing Criteria
(Criteria Are to Be Maintained From Screening to Completion of Study 
Dosing Phase)
ImmunosuppressantsaGenerally, agents must be dosed for at least 12 weeks before screening, with 
stable dosing for at least 8 weeks before the first dose of TAK -079 or matching 
placebo.
Regimens consisting of < 2agents w hile on study (not applicable to topical 
agents; see dose restrictions outlined in Table 7.a). 
Azathioprine 1 to 2 mg/kg/d
Mycophenolate mofetil 1 to 2 g/d
Methotrexate 7.5 to 25 mg/wk.
Corticosteroid aStable dosing equivalent to ≤20mg/day  of oral prednisone maintained 
for≥28days prior to the first dose of TAK -079 or matching placebo.
Antimalarials Stable dosing maintained for ≥28days and is likely to maintain the current dose 
throughout the dosing period, as determined by the principal investig ator. 
aDose limitations not applicable to topical agents.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 46of 110
Protocol Incorporating Amendment No 01 19 February 2019
Criteria for Discontinuation or Withdrawal of a Patient 7.4
Laboratory  findings in which TAK -079 dosing should be temporarily held, or permanent ly 
discontinued, are outlined in Table 6.b. Pati ents exhibit ing these or other clinical findings for 
which the principal investigator considers that continued TAK -079 dosing may place the pat ient at 
undue risk, should be i mmediately held fro m further TAK -079 dosing and continue to be fo llowed 
for safet y. In such instances, TAK -079 may be resumed under consultation with the study MM and 
in accordance to protocol -defined dosing criteria.
Treatment with study  drug m ay be disco ntinued permanent ly for any of the fo llowing reasons: 
AE and/or SAE.
Withdrawal by subject.
Protocol  violation.
Study  terminated by  sponsor.
Lost to follow -up.
Other.
Once study  drug has been discont inued, all study procedures outlined for follow up will be 
completed as specified in the schedule o f events (SOE) (see Table 3
.b). Patients withdrawing fro m 
study  treatm ent will be asked if they will permit follow -up assessment or not. If the patient 
completely wi thdraws consent, no further follow -up assessments can be completed. The primary 
reason for study  drug di scont inuat ion will be recorded on the eCRF. 
Procedures for Discontinuation or Withdrawal of a Patient 7.5
Patients wi thdrawing fro m study  dosing shoul d remain on study , com pleting all assessments and 
procedures associated with the 12 -week safet y follow-up period. If the prin cipal  invest igator or 
patient determines i t’s in the pat ient’s best interest to withdraw fro m the study , procedures and 
assessments associated with a final study  visit, as outlined in Table 3.b, shoul d be com pleted.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 47of 110
Protocol Incorporating Amendment No 01 19 February 2019
8.0 CLINICAL STUDY MATER IAL MANAGEMENT
Refer to the pharmacy  manual for detailed instructions regarding the storage and preparation of 
TAK -079 study  supply.
Clinical Study Drug 8.1
TAK -079 is a recombinant human Ig G1 mAb supplied as 100 mg TAK -079 in 1 mL (100 mg/mL) 
solution, to be administered as a single SC inject ion every 21 days (ie, 3 weeks) over the course of 
12 weeks for 4 total doses as part of each study  cohort.
TAK -079 drug product and matching placebo ar e supplied in aseptically filled, single -use, clear, 
typeI, borosilicate glass vials wit h fluoropolymer -coated butyl rubber stoppers and aluminum 
crimp seals wit h flip-off caps .
8.1.1 Clinical Study Drug Labeling
Supplies of TAK- 079 and m atching placebo are lab eled according to the current International 
Council for Harmonisat ion of Technical Requirements for Pharmaceut icals for Human Use (ICH) 
guidelines on Good Clinical Practices (GCP) and Good Manufacturing Practices (GMP) and 
include any  locally requi red stat ements. 
8.1.2 Clinical Study Drug Inventory, and Storage 
8.1.2.1 Receipt of Study Drug 
The invest igator is responsible for ensuring that deliveries of TAK- 079 and other study  materials 
from the sponsor are correctly  received, recorded, and handled, and stored safely  and properly in 
accordance with the Code of Federal Regulat ions (CFR) or national and local regulat ions, and used 
in accordance wit h this protocol .
During shipping, vials are to be protected from light and maintained within temperatures provided 
in the Pha rmacy Manual. Each TAK -079 shipment incl udes a packing slip list ing the contents of 
the shipment, and any applicable forms. The investigator or designee must confirm that 
appropriate temperature condit ions have been maintained for all TAK -079 and matching placebo 
received and that any discrepancies are reported and resolved before use of TAK -079 or matching 
placebo.
Upon recei pt of study  medicat ion, the invest igator or designee must verify the contents of the 
shipments against the packing list. The verifier shoul d ensure that the quantit y is correct, the 
medicat ion is received within the labeled storage condit ions, and is in good condition. If quant ity 
and condit ions are acceptable, invest igator or designee should acknowledge the receipt of the 
shipment by  signing bottom half o f the packing list and faxing per instructions provided on the 
form. If there are any discrepancies between the packing list versus the actual product received, 
Takeda must be contacted to resolve the issue. The packing list should be f iled in the invest igator’s 
essent ial docum ent file.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 48of 110
Protocol Incorporating Amendment No 01 19 February 2019
The sponsor must be notified immediately  of any tem perature excursio ns, shipping and handling 
or storage discrepancies.
8.1.2.2 Storage of Study Drug
All clinical trial material must be kept in an appropriate, li mited -access, secure location unt il used 
or returned to the sponsor or designee. 
TAK -079 and matching placebo must be stored according to the manufacturer’s stipulat ion, as 
specified on the label, and remain in the original container unt il dispensed. As s uch, TAK -079 
drug product and matching placebo must be stored under condit ions outlined in the pharmacy 
manual. A daily  temperature l og of  the drug storage area must be maintained every  day.
8.1.2.3 Study Drug Dispensing and Inventory 
The principal invest igator or desi gnee m ust ensure that the study  medicat ion (ie, TAK -079 and 
matching placebo) is used in accordance wit h the approved protocol and is dispensed only to 
patients enrolled in the study . To docum ent appropri ate use of study  medicat ion (TAK -079), the 
investi gator m ust m aintain records of all study medicat ion (1) delivered to the site, (2) maintained 
in site inventory , (3) di spensed/used by  each patient, and (4) returned to the sponsor or designee .
Detailed dosage preparation instructions are provided in the directions f or use secti on of  the 
pharmacy manual. Co mplete recei pt, inventory , accountabili ty, reconciliat ion, and destruction 
records must be maintained for all used and unused study drug vials. Detailed instructions and the 
associ ated f orms for thes e activit ies are in the pharmacy manual.
Drug supplies are to be counted and reconciled at the site before being returned to Takeda or 
designee or being destroy ed.
The invest igator will be notified of any expiry date or retest date extensio n of clinical st udy 
materi al during the study  conduct. On expiry date notification from the sponsor or designee, the 
site must com plete all instructions outlined in the notification, including segregat ion of expired 
clinical study  material for return to the sponsor or its designee.
Further gui dance and information are provided in the pharmacy  manual .
8.1.3 Clinical Study Drug Blinding
The assignment of study  patients to one of two study  arms, wi thin each cohort, is maintained 
through a blinded rando mizat ion schedule, available, in instances of medical emergencies, to the 
principal investigator. Otherwise site staff, will remain blinded through the conduct of the study . 
Details on maintaining the study  blind, and unblinding procedures are outlined in Section 8.1.5 .
8.1.4 Randomization Code Creation and Storage
The rando mizat ion and m edicat ion schedule will be generated and maintained by an interact ive 
voice/web response system (IX RS). All rando mization information will be stored in a secured 
area, accessible only by  authori zed personnel. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 49of 110
Protocol Incorporating Amendment No 01 19 February 2019
8.1.5 Clinical Trial Blind Maintenance/Unblinding Procedure
To maintain the integri ty of the study , all study  personnel, including the investigators, s ite 
personnel, the contract research organizat ion medical mo nitor, study  clinicians, and the sponsor, 
will be blinded to the treatment assignments during the treatment period. Treatment assignments 
will be obtained through the IXRS according to th e procedu res outlined in the study  manual . 
Inform ation regarding the treatment assignments will be kept securely at Takeda or designee, per 
its standard operating procedures. 
Records of the patient number, the date the study  drug was dispensed, and the treatment 
assignment will be maintained by the study  site.
Emergency  unblinding, if necessary, will be conducted via the IXRS. The following provides 
key factors to be considered regarding breaking the study  blind: 
–If the treatment assignment must be revealed for th e safet y of the patient, to treat an AE, or 
to inform decisio ns for subsequent therapy , the investigator will contact the Takeda project  
clinician or designee (in accordance to contact informat ion and procedures outlined in the 
study  manual). 
–A decisio n to break the blind must be reached by the Takeda project clinician or designee 
and the invest igator. The invest igator, or designee, may break the blind through the IXRS 
independent of the Takeda project clinician or designee only  if the invest igator conside rs 
the situation to be an em ergency and requires specific knowledge of the blinded study  
treatm ent to properly treat the AE/safet y issue. 
–If the treatment of the AE/safet y issue is ant icipated to be the same regardless of study drug 
assignment, the blind shoul d not be broken. 
–The event requiring breaking the blind must be documented in the eCRF, including the date 
the blind was broken. 
–After breaking the blind, the patient will be discontinued fro m further study  drug 
administration in this study . 
8.1.6 Accoun tability and Destruction of Sponsor- Supplied Drugs
The invest igator, institution, or head of the medical inst itution (where applicable) is responsible 
for TAK -079 accountabilit y, reconciliat ion, and record maintenance (ie, receipt, reconciliat ion, 
and fina l disposit ion records).
The principal invest igator must maintain 100% accountabilit y for all study  medicat ion (TAK -079 
and matching placebo) received and dispensed during his or her ent ire parti cipat ion in the study. 
Proper drug accountabilit y includes, bu t is not limited to:
Continuously mo nitoring expiration dates if expiry date/retest date is provided to the 
investigator.
Frequent ly verifying that actual inventory  matches docum ented inventory .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 50of 110
Protocol Incorporating Amendment No 01 19 February 2019
Verifying that the log is completed for the drug lot used to prepare each dose.
Verifying that all containers used are documented accurately on the log.
Verifying that required fields are co mpleted accurately and legibly.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediat ely.
Empty, parti ally used, and unused TAK -079 are to be disposed of, retained, or returned to the 
sponsor or designee, as detailed in the pharmacy manual. 
The invest igator must maintain a current inventory (drug accountabilit y log) of  all 
sponsor -supplied study medicat ion delivered to the site, the ongoing inventory at the site, and the 
patients’ usage records. This log must accurately  reflect the drug accountabilit y of the study  
medicat ion at all times. The fo llowing inform ation, at minimum, will be recorded: protocol 
number and tit le, name of invest igator, site ident ifier and number, descript ion of sponsor -supplied 
medicat ion, expiry/retest date, and amount dispensed, including the init ials of the person 
dispensing and receiving the study  medicat ion. The log should include all required informat ion as 
a separate entry  for each pati ent to whom  study  medication is dispensed.
Further gui dance and information are provided in the pharmacy  manual .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 51of 110
Protocol Incorporating Amendment No 01 19 February 2019
9.0 STUDY PROCEDURES
Assessments and procedures should be perf ormed on schedule, within the timeframe and window 
allowance in Table 3.a , Table 3.b, and Table 3.c. Further time allowance for most study procedures 
and assessments, except for PK draw times, are acceptable in extenuat ing circumstances (ie, 
holidays, vacat ions, and other administrative rea sons) on approval by the MM or delegate; 
however, these time extensio ns should not deviate more than 7 days from the scheduled 
procedural  time.
Administrative Procedures 9.1
9.1.1 Informed Consent Procedure
Each patient must provide written informed consent before a ny study -requi red procedures are 
conducted, unless those procedures are performed as part of the patient’s standard care .
9.1.2 Assignment of Randomization Numbers 
At the time of rando mization, after completion of all screening assessments and procedures and 
confirmation of eligibilit y, pati ents are assigned a 4 -digit randomizat ion sequence number. 
Randomization numbers are generated by  the sponsor or designee. Rando mized schedules are 
available to the unblinded study  stati stician.
9.1.3 Study Drug Assignment
Patientsare randomly assigned in a 3:1 ratio to one of the two study arms as outlined in Figure 2.a
at the complet ion of study  screening and before dosing on study  Day  1, in accordance to the 
rando mizat ion schedule as generated by the sponsor or designee. Rando mizat ion informat ion is 
stored in a secured area, accessible only by authorized personnel, to include the unblinded study  
statist ician, and necessary site staff in inst ances of emergency un- blinding (as outlined in 
Secti on8.1.5).
Clinical Procedures and Assessments 9.2
9.2.1 Inclusion and Exclusion
Eligibilit y criteria and associ ated screening study  assessments m ust be confirmed during the 
screening period, after a patient has signed the ICF, and before receiving study  drug.
Principle invest igators must provide the study MM a summary o f key eligibilit y criteria for review 
soeligibilit y can be verified before enrolling each patient. 
9.2.2 Medical History and Demography
A complete medical history is co mpiled for each patient during the screening period (ie, ≤28days 
before study  Day 1) and includes assessment and documentation of p rior medical  history , 
comorbidi ties and concomitant treatments. This includes assessments of current SLE signs, 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 52of 110
Protocol Incorporating Amendment No 01 19 February 2019
symptoms, morbidit ies, as evaluated and scored by disease act ivity tools and previous and current 
SLE therapies (see Section 9.3.4 ).
Dem ographics will include the date of birth, race, ethnicit y, and sex of the patient during 
screening. 
9.2.3 Concomitant Medications and Procedures
Concomitant medi cations, blood products, and procedures will be recorded fro m the first dose of 
TAK -079 or m atching placebo, through the end of the safet y follow-up peri od (ie, end of safet y 
follow-up visit in Week 24 or, when applicable, end of lo ng-term safet y follow-up visit in 
Week 36). Trade name and internat ional nonproprietary  name (if available), indicat ion, and start 
and end dates of the administered medicat ion are to be recorded. 
9.2.3.1 Background SLE Therapy 
Eligible pat ients will have received SLE background therapy for ≥12weeks (with stable dosing 
≥8weeks), before screening. Once enro lled into the study , pati ents will  remain on background 
therapy , as m anaged by  their principal invest igator, in accordance wit h local institutional 
practi ces, and in alignment with th e study  protocol , throughout study  partici pation. Background 
SLE therapy ongo ing at the time of screening will be recorded in the eCRF, as will any changes to 
this therapy . 
9.2.4 Physical Examination
A symptom -directed physical  examinat ion with assessments for SLE signs and symptoms will be 
completed in accordance wit h standard o f care at the times specified in the SOE (see Table 3.aand 
Table 3.b). 
9.2.5 Vital Signs
Vital signs include body  temperature, pul se, respi ratory  rate (RR), and BP. These are to be 
evaluated at visits specified in the SOE Table 3.
aand Table 3.band recorded both on the source 
docum entati on and in the eCRF. In addit ion, vital signs should also be assessed at any  time it is 
clinically warranted, either in the clinic or home visit setting (ie, patient exhibits signs or 
symptoms of inject ion react ion, CRS, or hy persensi tivity react ions). As indicated in these tables, 
vital signs are to be asse ssed before each study  dose and 4 hours after dosing, as part of postdose 
assessments. 
Pulse and BP should be assessed in similar positions at each study  assessment. 
Clinically significant values, as determined by the principal investigator, must be docum ented as 
an AE and closely monitored for fo llow
-up. 
NOTE: Addi tional vital signs to include BP m easures shoul d be assessed at any  time the patient 
reports symptoms consistent with an infusio n reactio n. If the patient experiences hypotensio n 
(with or without symptom s), intensive BP monitoring according to local pract ice should be 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 53of 110
Protocol Incorporating Amendment No 01 19 February 2019
instituted. The patient should not be released fro m the study  site unt il BP values have returned to 
Grade 1 or baseline for at least 1 hour.
9.2.6 12-Lead Electrocardiogram
Each ECG recordi ng shoul d be performed according to standard inst itutional pract ice.
All study  ECGs, to include triplicate ECGs, are interpreted by a qualified person (ie, read locally). 
Further, tri plicate 12 -lead ECGs are recorded electronically and are to be s ubmitted to a central 
vendor for storage and for future analysis. 
ECGs wi th clinically significant findings, as judged by  the invest igator, are to be considered a 
TEAE; (except for ECGs obtain edas part of the screening) visit which would be considered pa rt of 
medical history ). Clinically significant findings are to be recorded on the source documentation 
and in the eCRF, and undergo continued mo nitoring as described in Sect ion10.2.5
A single 12- lead ECG is to be collected at the screening visit (for asse ssment of eligibilit y) and at 
the end of safet y follow-up visit . 
Triplicate 12 -lead ECGs, obtained before each study  dose, are to be collected just before PK 
sampling, during timeframes outlined in
 Table 3.aand Table 3.b.  Triplicate ECGs will be stored 
centrally  for future analysis. 
When the timing of the triplicate and single (safet y) ECGs coincide, the site can use the triplicate 
ECG collect ion for the saf ety evaluat ion. 
9.2.7 AE Monitoring
Moni toring of TEAEs, seri ous and nonserious, are to be conducted throughout the study  as 
specified in the SOE (see Table 3.
aand Table 3.b) . Ref er to Secti on10.0 for details regarding 
definit ions, docum entati on, and reporting of TEAEs and SAEs.
Dosing criteria assessment will be co mpleted as per Table 6.
bto ensure pati ents m eet parameters 
before study  dosing. 
9.2.8 Laboratory Procedures and Assessments
Unless otherwise stated in the protocol, all laboratory  samples, with except ion to Coombs tests, are 
to be sent to the study  central  laboratory  for analysis, un der the condi tions f or handling and 
shipping as outlined in the study  laboratory  manual . Coombs test will  be done l ocally . 
9.2.8.1 Clinical Laboratory Tests
Clinical laboratory evaluat ions are obtained, handled, stored, and shipped to the designated central 
labor atory , in accordance to the laboratory manual. Clinical chemistry and hematologic assays are 
outlined Table 9.aand urinalysis assays are outlined in
 Table 9.b.  Timings of these assessments 
shoul d be in accordance to the study  SOE (see Table 3.aand Table 3.b). 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 54of 110
Protocol Incorporating Amendment No 01 19 February 2019
Table 9.a Clinical Chemistry and Hematology Assessments
Hematology Serum Chemistry
ANC
Hematocrit
Hemoglobin
Platelet count 
WBC count 
WBC with differential
Coagulation panel
Coom bs test (both direct and 
indirect)Albumin
ALP
ALT
AST
Bilirubin (total) 
BUN
Calcium
Chloride
CO2 (bicarbonate)
Creatinine CRP
Glucose (nonfasting) 
LDH
Potassi um
Sodium
Total protein
Urate (uric acid) 
Glomerular filtration rate
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, 
aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C -reactive protein; LDH, lactate dehydrogenase; WBC, 
white blood cell. 
9.2.8.2 Glomerular Fil tration Rate
The GFR should be calculated using the MDRD formula, as fo llows: 
   	 =175	 ×	(      	           )  .   	× 	(   )  .   	
For female patients, mult iply sum by  0.742.
For African American pat ients, multiply sum  by 1.212.
9.2.8.3 Urinalysis
A full urinalysis  will be conducted by  the study  central  
laboratory , as defined in Table 9.b, and are to be performed as part of the predosing assessment 
1week before each dosing day, and on each fo llow-up safet y visit (see
 Table 3.aand Table 3.b)  
Subsequently, on each dosing day, before dosing, and on each safet y follow-up visit, urine should 
be assessed for the presence of protein and nitrates as analyzed by the local laboratory (ie, dipst ick 
analysis) . 
Any abnormal findings from the local laboratory  urine  assessments 
shoul d be f ollowed by  a confi rming evaluat ion by the study  central  laboratory . The central  
laboratory  will perform urine microscopy  if the urinalysis is abnorm al. Microscopy  consists of 
RBC/high -power field, white blood cells (WBC)/high -
power field, and casts.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 55of 110
Protocol Incorporating Amendment No 01 19 February 2019
Table 9.b Clinical Urinalysis Assessments
Urinalysis 
Bilirubin
Glucose
Ketones
Leukocytes
Nitritea
Occult bloodpH
Protein  a
Specific gravity
Turbidity  and color
Urobilinogen
a Protein and nitrates are to be assessed as part of the full urinalysis, analyzed by the central laboratory 1 week before 
each dosing da y. In addition, before dosing on study dosing days, protein and nitrates should be assessed by local 
laborato ry (ie, dipstick). Abnormal findings by local laboratory assessment must be confirmed by full urinalysis by 
central laboratory. Further details on assessment timings are provided in Table 3.aand Table 3.b .
9.2.9 Pregnancy Test
All study  pregnancy testing may  be conducted at a designated local laboratory  as determined and 
confirmed by the sponsor, with appropriate laboratory  docum entati on provi ded in advance of 
study  testing.
9.2.9.1 Definition of Women of Child -bearing Potential
A wo man of child -bearing potential is a sexually mature woman who: 
Has not undergone a hysterectomy or bilateral oophorectomy; or, 
Has not been naturally postmenopausal (amenorrhea following cancer therapy  does not rule 
out child -bearing potential) for at least 24 consecutive months (ie, has had menses at any time 
in the preceding 24 consecut ive months).
9.2.9.2 Timings of Pregnancy Testing 
Women of child- bearing potenti al must have pregna ncy testing co mpleted in accordance to the 
timings outlined as fo llows: 
Before Initial Study Dosing : 
–Screening period : a negative serum pregnancy tests (human chorionic gonadotropin [hCG] 
<5 m IU/mL) .
–Baseline :(within 24 hours before the start of study drug) a negative urine pregnancy test 
with a sensit ivity of at least 50 m IU/mL. If the urine test is indeterminate, a serum 
pregnancy test is mandatory .
During Study Enrollment :
–On each dosing day , before dosing; ( urine pregnancy test).
–End of dosing period , as outlined in Table 3.a(serum pregnancy test).
–During safety  follow-up period, as outlined in Table 3.b(serum pregnancy test).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 58of 110
Protocol Incorporating Amendment No 01 19 February 2019
Table 9.c End-of-Study Clinical Parameters
Safety Parameter Laboratory 
InvestigationsEnd-of-Study Criteria Continuation to Long -Term Follow -up
B cells ≥LLN or study baseline levels ≤LLN or study baseline levels that is directly 
related to dosing of investigational product. Neutrophils
Platelets
T cells
Hgb
IgG, IgA, and IgM levels 
Events of clinical interest
TAK -079–related infusion 
reaction (systemic signs and 
symptoms) to include CRS≤Grade 1 a≥Grade 2 reaction a
CRS leading to moderate clinical symptoms 
based on a global assessment of symptoms, as 
classified by the CTCAE version 4.03 
(symptoms to include but not be limited to 
headache, fever, chills/rigors, nausea, 
vomiting, diarrhea, arthralgia, myalgia, and 
hypotension)
Systemic infection ≥Grade 2 
Dosing is to be held until the infection is 
resolved 
Abbreviations: CRS, cytokine release syndrome; CTCAE, Common Terminology Criteria for Adverse Events 
(CTCAE); LLN, lower limit of normal. 
aGrading based on Lee, 2014 [17].
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 59of 110
Protocol Incorporating Amendment No 01 19 February 2019
10.0 ADVERSE EVENTS
Pretreatment Events 10.1
A pretreatment event (PTE) is defined as any untoward medical occurrence in a clinical 
investigat ion subject who has signed ICF form to participate in a study but before administration of 
any study  medicat ion; it does not necessarily  have to have a causal relationship wit h study  
participat ion. 
Definitions and Elements of AEs 10.2
An AE is defined as any untoward medical occurrence in a clinical invest igation subject who has 
signed ICF to participate in a study; it does not necessarily have to have a causal rela tionship wit h 
the treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug, whether or 
not it is considered related to the drug.
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a preexist ing condit ion (intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered PTEs or 
AEs).
Necessitate therapeutic intervent ion.
Requi re an invasive diagnosti c procedure.
Requi re discontinuation or a change in dose of study medicatio n or a concomitant medicat ion.
Be considered unfavorable by the invest igator for any reason.
Diagnoses versus signs and symptoms:
Each eve nt should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appro priately as a PTE(s) or an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG parameters maybe considered AEs if they are judged to 
be clinically  significant (i e, if som e act ion or intervent ion is required or if the investigator
judges the change to be beyo nd the range of normal physio logic fluctuati on). A l aboratory  
re-test and/or continued monitoring of an abnormal value are not considered an intervention. In 
addition, repeated or addit ional noninvasive testing for verificat ion, evaluat ion or m onitoring 
of an abnorm ality is not considered an intervention.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 60of 110
Protocol Incorporating Amendment No 01 19 February 2019
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis onl y shoul d be 
reported appropriately  as an AE.
Pre-exist ing condit ions:
A pre -exist ing condit ion (present at the time of signing of ICF) is considered a concurrent 
medical history  condit ion and should NOT be recorded as a PTE or AE. A baseline evaluat ion 
(eg, l aboratory  test, ECG, radi ograph) shoul d NOT be recorded as a PTE unless related to a 
study  procedure. However, if the subject experiences a worsening or complicat ion of such a 
concurrent medical history  condi tion, the worsening or complicat ion should be recorded 
appropriately  as a PTE (worsening or complicat ion occurs before start of study medicat ion) or 
an AE (worsening or complicat ion occurs after start of study medicat ion). Investigators should 
ensure that the event term recorded captures the chang e in the condit ion (eg, “worsening 
of…”).
If a subject has a pre -exist ing episodic condit ion (eg, asthma, epilepsy), any occurrence of an 
episode should only be captured as an PTE/AE if the episodes become more frequent, serious, 
or severe in nature, that is, invest igators should ensure that the AE term recorded captures the 
change from baseline in the condit ion (eg “worsening of…”).
If a subject has a degenerative concurrent condition (eg, cataracts, RA), worsening of the 
condi tion shoul d only be captured as a PTE/AE if occurring to a greater extent than that which 
woul d be expected. Again, investigators should ensure that the AE term recorded captures the 
change in the condit ion (eg, “worsening of…”).
Worsening of AEs:
If the subject experiences a worsenin g or complicatio n of a PTE aft er the first administration of 
study  medicat ion, or a worsening or complicat ion of an AE after any  change in study  
medicat ion, the worsening or complicat ion should be recorded as a new AE. Investigators 
shoul d ensure that the AE term  recorded captures the change in the condit ion (eg, “worsening 
of…”).
Changes in severit y of AEs:
If the subject experiences a change in the severit y of an AE that is not associated with a change 
in study  medicati on, the event shoul d be captured onc e with the m aximum  severi ty recorded.
Prepl anned surgeries or procedures:
Prepl anned procedures (surgeries or therapies) that were scheduled before signing of ICF are 
not consi dered AEs. However, if a preplanned procedure is performed early (eg, as an 
emergency) due to a worsening o f the pre -existing condit ion, the worsening of the condit ion 
shoul d be captured appropriately as an AE. Complications result ing fro m any planned surger y 
shoul d be reported as AEs.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 61of 110
Protocol Incorporating Amendment No 01 19 February 2019
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as AEs but should be documented in the subject’s source documents. 
Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Overdose:
An ov erdose is defined as a known deliberate or accidental administration of investigational 
drug, to or by  a study  subject, at a dose above that which is assigned to that individual subject 
according to the study  protocol . 
All cases of overdose (with or witho ut associated AEs) are to be documented on an overdose 
page of the (e)CRF to capture this important safet y informat ion consistent ly in the database. 
AEs associated with an overdose will be documented on AE CRF(s) according to Section 10.0.
SAEs of overdose should be reported according to the procedure outlined in Sect ion10.2.6 .
In the event of drug overdose, the subject should be treated symptomat ically.
If an overdose does occur, close monitoring and supportive treatment as medically required are 
recommended.
10.2.1 SAEs
An SAE is defined as any unto ward medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOSPITALIZATION or prolongation of exist ing hospitalizat ion.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satis fies any of the fo llowing:
May require intervent ion to prevent the preceding items 1 through 5.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
Includes any event or synonym described in the Takeda Medically  Significant AE List 
(Table 10.a).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 62of 110
Protocol Incorporating Amendment No 01 19 February 2019
Table 10.a General List of Takeda Me dically Significant AEs
Term
Acute respiratory failure/acute respiratory 
distress syndromeHepatic necrosis
Acute liver failure
Torsade de pointes/ventricular fibrillation / 
ventricular tachycardiaAnaphy lactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizures Pulmonary fibrosis
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent by 
a medicinal product Toxic epidermal necrolysis/Stevens -Johnson syndrome
Neuroleptic malignant syndrome/malignant hyperthermia
Spontaneous abortion/stillbirth and fetal death
AEs that fulfill 1 or more of the preceding serious criteria are to be considered SAEs and should be 
reported and fo llowed in the same m anner (see Secti on10.2.1 ).
10.2.2 AEs of Clinical Interest 
AEs of clinical interest are based on the mechanism o f action of TAK -079, reports from other 
biologic agents, the nonclinical data to date, and the limited data fro m Study  TAK -079- 101 in 
healt hy human subjects. These AEs may include, but are not limited to, the fo llowing: ISRs, CRS, 
hypersensit ivity react ions, changes in hematologic paramete rs, and infect ions. Patients will be 
monitored cl osely  for these AEs in clinical studies with TAK -079. Refer to Section 6.5for a 
discussio n of the se events and recommendat ions on the Management of Events of Clinical 
Interest, and Section 6.2.1 for a descript ion of the required premedications before TAK -079 
dosing. Section 4.4provides a summary of the overall benefit -risk profile. 
10.2.3 Assigning Severity/Intensity of Adverse Events
The diffe rent categori es of severit y/intensity are:
Table 10.b AE Definitions for Severity/Intensity by Category
Mild An AE that is usually transient and may require only minimal treatment or therapeutic 
interventi on. The event does not generally interfere with usual activities of daily living.
Moderate An AE that is usually alleviated with additional specific therapeutic intervention. The event 
interferes with usual activities of daily living, causing discomfort b ut poses no significant or 
permanent risk of harm to the research participant.
Severe An AE that interrupts usual activities of daily living, significantly affects clinical status, or may 
require intensive therapeutic intervention.
Abbreviation: AE, adverse event.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 63of 110
Protocol Incorporating Amendment No 01 19 February 2019
10.2.4 Assigning Causality of Adverse Events
The rel ationship of each AE to study  medicati on(s) will be assessed using the fo llowing 
categori es:
Table 10.c AE Definitions for Causality 
Related An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of the drug), or for which a causal relationship is at least a reasonable 
possibility (ie, the relationship cannot be ruled out , although fa ctors other than the drug, such as 
underlying diseases, complications, concomitant drugs and concurrent treatments, may also be 
responsible).
Not related An AE that does not follow a reasonable temporal sequence from administration of a drug 
and/o r that c an reasonably be explained by other factors, such as underlying diseases, 
complications, concomitant medications and concurrent treatments.
10.2.5 Collection and Reporting of AEs, SAEs, and AEs of Clinical Interest
10.2.5.1 Collection Period
Collect ion of AEs (ie, AEs, S AEs, AEs of clinical interest, and abnormal liver funct ion tests) will 
commence at the time the subject signs the ICF. AEs ongoing at EOT should be monitored until 
they are resolved, return to baseline, are clearly  determined to be due to a patient’s stabl e or 
chronic condit ion or intercurrent illness(es), or 6 months after EOT has occurred, whichever 
comes first . For patients who withdraw before the administration of study medicat ion, AEs will be 
followed unt il the subject discontinues study  parti cipat ion.
10.2.5.2 Reporting AEs
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeling since your last visit ?” may be asked. 
Subjects m ay report AEs occurri ng at any  other time dur ing the study. Patients experiencing an 
SAE before the first exposure to investigational product must be monitored until the symptoms 
subside and any clinically relevant changes in laboratory values have returned to baseline, or until 
there is a satisfacto ry explanat ion for the change. Nonserious AEs that begin before the first 
exposure to invest igational product, related or unrelated to the study  procedure, need not be 
monitored for the purposes of the protocol.
All pat ients experiencing AEs, whether considered associated with the use of the study medicat ion 
or not, m ust be m onitored until the symptoms subside and any clinically  relevant changes in 
laboratory  values have returned to baseline or until there is a sat isfactory  explanat ion for the 
changes observed. All AEs will be documented in the AE page of the eCRF, whether or not the 
investigator concludes that the event is related to the drug treatment. The fo llowing informat ion 
will be documented for each event:
Event term .
Start and end date and time .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 64of 110
Protocol Incorporating Amendment No 01 19 February 2019
Pattern of AE (frequency).
Severit y/intensity.
Causalit y (investi gator’s opi nion of the causal relatio nship between the event and 
administration of study  drug[s]).
Action taken with trial drug.
Outcom e of event.
Seriousness.
10.2.5.3 Reporting SAEs
When an SAE oc curs through the AE collection period, it should be reported according to the 
following procedure:
A Takeda SAE form must be co mpleted, in English, and signed by the investigator immediately or 
within 24 hours of first onset or notification of the event. T he informat ion should be co mpleted as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the reason why  the event i s categori zed as serious.
Subject identificat ion number.
Invest igator’s name.
Nam e of the study  medicat ion(s).
Causalit y assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed as 
follows:
SAE Reporting Contact Informat ion
Cogni zant
United States and Canada
Toll-free fax #: 1-800-963-6290
E-mail: takedaoncocases@cogniz ant.com
Any SAE spontaneously reported to the invest igator fo llowing the AE collect ion period should be 
reported to the sponsor if considered related to study  parti cipat ion.
Reporting of SAEs that begin before first administration of investigational produc t will fo llow the 
same procedure for SAEs occurring on treatment.
SAE Follow -up
If informat ion is not available at the time o f the first report becomes available at a later date, the 
investigator should complete a fo llow-up SAE form  or provi de other wri tten documentation and 
fax it immediately wit hin 24 hours of receipt. Copies of any relevant data from the hospital notes 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 65of 110
Protocol Incorporating Amendment No 01 19 February 2019
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) should be sent to the 
addressee, if requested.
All SAEs should be mon itored until resol ution or perm anent outcom e of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.2.6 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities 
The sponsor will be resp onsible for reporti ng all suspected unexpected SAEs and any  other 
applicable SAEs to regulatory  authorit ies, investigators and IRBs or independent ethics co mmittee 
(IECs), as applicable, in accordance with nat ional regulat ions in the countries where the st udy is 
conducted. Relat ive to the first awareness of the event by/or further provisio n to the sponsor or 
sponsor’s designee, Serious Unexpected Serious Adverse React ion (SUSAR) reports will be 
submitted wi thin 7 days for fatal and life -threatening events a nd wi thin15 days for other serious 
events, unless otherwise required by nat ional regulations. The sponsor will also prepare an 
expedited report for other safet y issues where these might materially alter the current benefit- risk 
assessment of an investigati onal medicinal product or that would be sufficient to consider changes 
in the invest igational medicinal products administration or in the overall conduct of the trial. The 
investigat ional site also will forward a copy  of all expedited reports to his or her IRB or IEC in 
accordance with nat ional regulat ions.
Drug Safety Monitoring Board 10.3
In accordance with Takeda standard procedures, each clinical trial is evaluated to determine if a 
Drug Safet y Moni toring Board (DSMB) should be convened. Applicable regulat ion and guidance 
are used to evaluate each trial in terms of potential confounding f actors that complicate evaluatio n 
of the study safet y and/or efficacy data, and potential risks of the study design or treatm ent to study 
participants [25].A DSMB is not indicated at this time for this study given that Takeda’s standards 
and processes, which include cont inuous review and evaluat ion of safet y data reported from all 
participat ing sites through the conduct of the study, are appropriate for the ongoing monitoring o f 
patient safet y and data integrit y. Addi tionally, as noted in detail in Sect ion6.3, Takeda clinicians/ 
designee conduct ongoing safet y oversight at the patient and study level as well as rev iew o f safety 
of a full cohort in the dose escalat ion phase. However, taking into considerat ion the evo lving 
benefit -risk profile of TAK -079, the deci sion to convene a DSMB could be taken at any  time 
during the conduct of Study  TAK -079-2001.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 68of 110
Protocol Incorporating Amendment No 01 19 February 2019
related AEs. AEs l eading to study  drug di scont inuation and SAEs will be listed. Data list ings will 
be provided for all AEs including PTE, TEAEs, AEs leading to study drug discont inuat ion, and 
SAEs.
11.1.6.2 Clinical Laboratory Evaluation
Individual result s of l aboratory  tests fro m hematology , chemistry , and urinalysis that meet 
abnorm al criteria to be defined in the SAP will be listed and summarized. Baseline, postdose, and 
change from baseline to postdose laboratory  data will  be summarized. All clinical laboratory  data 
will be listed. Clinical significant laboratory  resul ts will be captu red as AEs.
11.1.6.3 Vital Signs
Individual result s of vital signs that meet abnormal criteria will be defined as an AE as per the 
principal invest igator; to be defined in the SAP will be listed and summarized. Baseline, post -dose, 
and change fro m baseline in vital sign measurements will be summarized. All vital signs data will 
be provided in the data list ings.
Interim Analysis and Criteria for Early Termination 11.2
No interim analysis is planned.
Determination of Sample Size 11.3
This study is not statist ically powered for any hypothesis testing. The sample size o f 6 act ive and 2 
placebo pati ents f or each of the 45 mg, 90 mg, and 135 mg dose groups (Cohorts A, B, and C, 
respectively ) are considered to be sufficient to fulfill the study object ives o f the evaluat ion of 
safet y,tolerabili ty, and PK of each cohort.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 69of 110
Protocol Incorporating Amendment No 01 19 February 2019
12.0 QUALITY CONTROL AND QUALITY ASSURANCE
Study Site Monitoring Visits 12.1
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. Source document s will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and study site guarantee access to source documents by the sponsor or its 
designee contract research organi zation and by the IRB or IEC.
All aspects of the study  and i ts docum entati on will be subject to review by the sponsor or the 
sponsor’s designee (as long as blinding is not jeopardized), including but not limited to the 
investigator’s binder, trial drug, patient medical records, ICF documentation, and review of eCRFs 
and associated source documents. It is important that the invest igator and other study personnel are 
available during the monitoring visit s and that sufficient time is devoted to the proce ss.
Protocol Deviations 12.2
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to trial pat ients. Shoul d other unexpected circumstances arise that will require 
deviat ion from protocol -specified proced ures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
Significant deviat ions include, but are not limited to, those that invo lve fraud or misconduct, 
increase the healt h risk to the pati ent, or confound interpretation of primary study  assessment. 
Quality Assurance Audits and Regulatory Agency Inspections 12.3
The stud y site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where labora tory samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg , the Food and Drug Administration [FDA], the United Kingdo m 
Medicines and Healthcare Products Regulatory Agency, the Pharmaceut icals and Medical Devices 
Agency o f Japan). If the study site is contacted for an inspect ion by a regulatory body, the sponsor 
should be notified immediately. The invest igator guarantees access for qualit y assurance auditors 
to all study  docum ents as described in Section 12.1.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 70of 110
Protocol Incorporating Amendment No 01 19 February 2019
13.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, subjects, 
patients) according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the I CH Harmonised Tripart ite Guideline for GCP. Each investigator will conduct 
the study  according to applicable local or regional regulatory  requi rements and align his or her 
conduct in accordance wit h the “Responsibilit ies of the Invest igator” that are liste d in Appendix D. 
The principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for ICF and invest igator responsibilit ies.
IRB and/or IEC Approval 13.1
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing regio n. The sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those American sites unwilling to provide names and tit les of all 
members due to privacy  and conflict of interest concerns should instead provide a Federalwide 
Assurance Number or comparable number assigned by the Department of Health and Human 
Services.
The sponsor or designee will supply relevant documents for submissio nto the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the investigator’s brochure, a copy of 
the ICF form, and, if applicable, subject recruit ment materials and/or advertisements and other 
docum ents requi red by  all applicable laws and regulat ions, must be submitted to a central or local 
IRB or IEC for approval. The IRB’s or IEC’s written approval o f the protocol  and subject ICF 
must be obtained and submitted to the sponsor or designee before commencement of the study (ie, 
before shipment of the sponsor -supplied drug or study specific screening act ivity). The IRB or IEC 
approval  must refer to the study by exact protocol title, number, and versio n date; ident ify versio ns 
of other documents (eg, ICF) reviewed; and state the approv al date. The sponsor will ship 
drug/notify site once the sponsor has confirmed the adequacy o f site regul atory  docum entati on 
and, when applicable, the sponsor has received permissio n from co mpetent authorit y to begin the 
trial. Until the si te receives drug /notification no protocol act ivities, including screening, may  
occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the ICF, recrui tment 
materi als intended for viewing by  patients, l ocal safet y reporti ng requirements, reports and 
updates regarding the ongoing review of the study  at intervals specified by the respect ive IRB or 
IEC, and submissio n of the invest igator’s final status repo rt to IRB or IEC. All IRB and IEC 
approval s and rel evant docum entati on for these items must be provi ded to the sponsor or its 
designee.
Subject incentives should not exert undue influence for participat ion. Payments to patients must be 
approved by  the IRB or IEC and sponsor.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 71of 110
Protocol Incorporating Amendment No 01 19 February 2019
Subject Information, Informed Consent, and Subject Authorization 13.2
Written consent documents will embody the elements of the ICF as described in the Declaration o f 
Helsinki and the ICH Guidelines for GCP and will be in accordance with all applicable l aws and 
regul ations. The ICF, subject authorizat ion form (if applicable), and subject informat ion sheet (if 
applicable) describe the planned and permitted uses, transfers, and disclosures o f the subject’s 
personal and personal healt h informat ion for purposes of conduct ing the study. The ICF and the 
subject informat ion sheet (if applicable) further explain the nature of the study, its object ives, and 
potenti al risks and benefi ts, as well  as the date info rmed consent is given. The ICF will detail the 
requi rements of the participant and the fact that he or she is free to withdraw at any  time wi thout 
giving a reason and without prejudice to his or her further medical care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and, if applicable, the subject authorizat ion form. The ICF, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) must be approved by both the IRB or IEC 
and the sponsor before use.
The ICF, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) 
must be written in a language fully co mprehensible to the prospective subject. It is the 
responsibilit y of the invest igator to explain the detailed elements of the ICF, subje ct authori zation 
form (if applicable), and subject informat ion sheet (if applicable) to the subject. Informat ion 
shoul d be given in both oral  and wri tten form  whenever possible and in the manner deemed 
appropriate by the IRB or IEC. In the event the subjec t is not capable of rendering adequate written 
ICF, then the subject’s legally acceptable representative may provide such consent for the subject 
in accordance wit h applicable laws and regulations.
The subject, or the subject’s legally acceptable represent ative, must be given ample opportunit y to: 
(1) inquire about details o f the study, and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will part icipate in 
the study, then the ICF and subject authorizat ion form (if applicable) must be signed and dated by 
the subject, or the subject’s legally acceptable representative, at the time of consent and before the 
subject enters into the study . The subject or the subject’s legally acceptable representative should 
be instructed to sign using their legal names, not nicknames, using blue or black ballpo int ink. The 
investigator must also sign and date the ICF and subject authorization (if applicable) at the time o f 
consent and prior to subject entering into the study; however, the sponsor may allow a designee o f 
the invest igator to sign to the extent permitted by applicable law.
Once signed, the original ICF, subject authorizat ion form (if applicable), and subject informat ion 
sheet (if applicable) will be stored in the investigator’s site file. The investigator must document 
the date the subject signs the ICF in the subject’s medical record. Copies of the signed ICF, the 
signed subject authori zation form (if applicable), and sub ject informat ion sheet (if applicable) 
shall be given to the subject.
All revised ICF must be reviewed and signed by relevant patients or the relevant patient’s legally 
acceptable representative in the same manner as the original informed consent. The date the 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 72of 110
Protocol Incorporating Amendment No 01 19 February 2019
revised consent was obtained should be recorded in the subject’s medical record, and the subject 
shoul d receive a copy  of the revised ICF.
Subject Confidentiality 13.3
The sponsor and designees affirm and uphol d the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical study  database or documentation via a unique ident ificat ion number. As 
permitted by all applicable laws and regulat ions, li mited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy of t he subject’s unique 
ident ificat ion number.
To com ply with Internati onal Council for Harmonisation o f Technical Requirement s for 
Pharmaceut icals for Hum an Use (ICH) Gui delines for GCP and to verify  com pliance wi th this 
protocol , the sponsor requires the invest igator to permit its monitor or designee’s monitor, 
representatives from any regulatory  authori ty (eg, FDA, Medicines a nd Healt hcare Products 
Regulatory  Agency, Pharmaceut icals and Medical Devices Agency), the sponsor’s designated 
auditors, and the appropri ate IRBs and IECs to review the subject’s original medical records 
(source data or documents), including, but not limi ted to, laboratory  test resul t reports, ECG 
reports, admissio n and discharge summaries for hospital admissio ns occurring during a subject’s 
study  participation, and autopsy reports. Access to a subject’s original medical records requires the 
specific autho rization of the subject as part of the informed consent process (see Section 13.2).
Copi es of  any subject source documents that are provided to the Sp onsor m ust have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
Publication, Disclosure, and Clinical Trial Registration Policy 13.4
13.4.1 Publication and Disclosure
Theinvestigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study. During and after the study, only the sponsor may make study 
inform ation available to other study  invest igators or to regulat ory agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tmentmaterials and/or adverti sements, is the sol e responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the clinical study  site agreement. I n the event of any discrepancy between the 
protocol  and the clinical study  site agreement, the clinical study  site agreement will  prevail.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 73of 110
Protocol Incorporating Amendment No 01 19 February 2019
13.4.2 Clinical Trial Registration 
To ensure that information on clinical trials reaches the public in a timely manner and to com ply 
with applicable l aws, regul ations and guidance, Takeda will, at a minimum register all 
intervent ional clinical tri als it sponsors anywhere in the worl d on ClinicalTri als.gov and/or other 
publicly  accessible websi tes before start of study , as defi ned in Takeda Policy/Standard . Takeda 
contact informat ion, along with invest igator’s cit y, state (for American investigators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registries, Takeda will assist call ers in l ocating study  sites cl osest to thei r homes by 
provi ding the investigator name, address, and phone number to the callers request ing trial 
inform ation. Once pat ients receive invest igator contact informat ion, they  may call  the si te 
requesting enrollme nt into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial enro llment, they should be referred to the s ponsor.
Any invest igator who objects to the sponsor providing this informatio n to callers must provide the 
sponsor with a written notice request ing that their informat ion not be listed on the registry site.
13.4.3 Clinical Trial Results Disclosure 
Takeda will po st the results of clinical trials on ClinicalTrials.gov or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulat ions.
Insurance and Compensation for Injury 13.5
Each subject in the study must be insured in acc ordance wi th the regulations applicable to the site 
where the subject is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to study  patients. Refer to 
the study site agreement regarding the sponsor’s policy on subject compensat ion and treatment for 
injury . If the invest igator has questions regarding this policy, he or she should contact the sponsor 
or sponsor’s designee.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 74of 110
Protocol Incorporating Amendment No 01 19 February 2019
14.0 ADMINISTRATIVE AND R EFERENCE INFOR MATION
Administrative Information 14.1
14.1.1 Study Contact Information 
Contact Type / Role Contact
SAE and pregnancy reporting Pharmacovigilance
Takeda Development Center Americas, Inc.
Fax: 224 -554-1052
Abbreviation: SAE, serious adverse event.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 75of 110
Protocol Incorporating Amendment No 01 19 February 2019
14.1.2 Investigator Agreement 
I confirm that I have read and that I understand this protocol, the invest igator’s brochure, package 
insert, and any other product information provided by the sponsor. I agree to conduct this study in 
accordance with the requirements of this pro tocol  and also to protect the rights, safet y, privacy, 
and well -being o f study  patients in accordance with the fo llowing:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clini cal Practi ce: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting SAEs defined in Section 10.2.6 of this protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the Invest igator Appendix D.
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Eof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 76of 110
Protocol Incorporating Amendment No 01 19 February 2019
14.1.3 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
study -related responsibilit ies tem plate. The vendors identified for specific study -related activit ies 
will perform these act ivities in full or in partnership wi th the sponsor.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 77of 110
Protocol Incorporating Amendment No 01 19 February 2019
15.0 LIST OF A BBREVIATIONS
ADA antidrug antibody(ies)
AE adverse events
AUC area under the concentration -time curve
BP blood pressure
CFR Code of Federal Regulations
Cmax maximum observed concentration 
COPD chronic obstructive pulmonary disease
CRS cytokine release syndrome
CTCAE Common Terminology Criteria for Adverse Events
%CV percent coefficient of variation
dsDNA double -stranded DNA
DSMB drug safety monitoring board
ECG electrocardiogram
eCRF electronic case report form (refers to any media used to collect study data 
[ie, paper or electronic])
ENA extractable nuclear antigens
FDA Food and Drug Administration
FEV 1 forced expiratory volume in 1 second
FIH first in human
FSH follicle -stimulating hormone
GCP Good Clinical Practices
GFR glomerular filtration rate
GLP Good Laboratory Practice 
GMP Good Manufacturing Practices
hCG human chorionic gonadotropin
ICF informed consent form
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use
IEC independent ethics committee
IRB institutional review board
IRR infusion -related reaction
ISR injection site reaction
IV intravenous
IXRS interactive voice/web response sy stem
LLN lower limit of normal
mAb monoclonal antibody 
MESF quantified in molecules of equivalent soluble fluorochrome
MDRD Modification of Diet in Renal Disease 
MedDRA Medical Dictionary for Regulatory Activities
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 78of 110
Protocol Incorporating Amendment No 01 19 February 2019
MM medical monitor
NK natural killer 
NOAEL no observed adverse effect level
PB plasmablast
PD pharmacodynamic
PK pharmacokinetics 
PPD purified protein derivative
PT preferred term
PTE pretreatment events
RA rheumatoid arthritis 
RBC red blood cell
RR respiratory  rate
RRMM relapsed/refractory multiple myeloma
SAE serious adverse event
SAP statistical analysis plan 
SC subcutaneous 
SD standard deviation
SLE systemic lupus erythematosus
SLEDAI -2K systemic Lupus Erythematosus Disease Activity Index 2000
SOE schedule of events
TB tuberculosis
TEAE treatment -emergent adverse event
TIGRA T-cell interferon -γ release assay
TNF -α tumor necrosis factor -alpha
ULN upper limit of normal
WBC white blood cell
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 79of 110
Protocol Incorporating Amendment No 01 19 February 2019
16.0 DATA HANDLING AND RECORDKEEPING
The full details o f procedures for data handling will be documented in the data management plan. 
AEs, m edical history , and concurrent conditions will be coded using MedDRA. Drugs will be 
coded using the World Healt h Organizat ion Drug Di ctionary.
CRFs (Electronic and Paper) 16.1
Com pleted eCRFs are requi red for each subject who signs an informed consent.
The sponsor or its designee will supply investigative sites with access to eCRFs. The sponsor will 
make arrangements to train appropriate site staf f in the use of the eCRF. These forms are used to 
transmit the informat ion collected in the performance o f this study  to the sponsor and regulatory  
authori ties. eCRFs must be completed in English. Data are transcribed direct ly onto eCRFs.
After complet ion of the entry  process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the new informat ion, 
ident ificat ion of the person making the correction, the date the correction was made, and the reason 
for change. Reasons for si gnificant correcti ons shoul d addi tionally be i ncluded. 
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the investigator must retain full 
responsibilit y for the accuracy and authent icity of all data entered on the eCRFs .
After the lock of the clinical study database, any change of, modificat ion of, or addit ion to the data 
on the eCRFs should be made by the investigator with use of change and modificat ion records of 
the eCRFs. The principal investigato r must review the data change for completeness and accuracy, 
and must si gn and date . 
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The sponsor or i ts designee will be permitted to rev iew the subject’s medical 
and hospital records pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs 
are the sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized representat ives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the sponsor.
Record Retention 16.2
The invest igator agrees to keep the records stipulated in Section 16.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing patients, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, incl uding the audi t trail, and de tailed records of drug disposit ion to 
enable evaluat ions or audits from regulatory  authori ties, the sponsor or its designees. Any source 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 80of 110
Protocol Incorporating Amendment No 01 19 February 2019
docum entati on printed on degradable thermal sensitive paper should be photocopied by the site 
and filed wit h the origin al in the subject’s chart to ensure long -term legibilit y. Furthermore, ICH 
E6 requires the invest igator to retain essent ial documents specified in ICH E6 until at least 2 years 
after the last approval of a market ing applicat ion for a specified drug indicat ion being investigated 
or, if an applicat ion is not approved, until at least 2 years after the invest igation is discont inued and 
regul atory  authori ties are notified. In addit ion, ICH E6 states that the study  records should be 
retained unt il an amount of ti me specified by applicable regulatory  requi rements or for a time 
specified in the clinical study  site agreement between the invest igator and sponsor.
Refer to the clinical study  site agreement for the sponsor’s requirements on record retention. The 
investi gator and the head of the institution should contact and receive written approval fro m the 
sponsor before disposing of any  such documents.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 81of 110
Protocol Incorporating Amendment No 01 19 February 2019
17.0 REFERENCES
1.Merrill JT, Manzi S, Aranow C, Askenase A, Bruce I, Chakravarty E, et al. Lupus co mmu nity 
panel proposals for optimising clinical trials: 2018. Lupus Sci Med 2018;5(1):e000258.
2.Rahman A, Isenberg DA. Sy stemic lupus ery thematosus. N Engl J Med 2008;358(9):929 -39.
3.D'Cruz DP. Systemic lupus ery thematosus. BMJ 2006;332(7546):890-4.
4.Lateef A, Petri  M. Unmet m edical  needs in systemic lupus ery thematosus. Arthrit is Res Ther 
2012;14 Suppl 4:S4.
5.Hoyer BF, Manz RA, Radbruch A, Hiepe F. Long -lived plasma cells and their contribut ion to 
autoimmunit y. Ann N Y Acad Sci 2005;1050:124-33.
6.Jacobi AM, Mei  H, Hoy er BF, Mum taz IM, Thi ele K, Radbruch A, et al. 
HLA -DRhigh/CD27high plasmablasts indicate active disease in pat ients with systemic lupus 
erythematosus. Ann Rheum Dis 2010;69(1):305-8.
7.Liu Z, Zou Y, Davidson A. Plasma cells in systemic lupus erythematosus: the long and short of 
it all. Eur J Immuno l 2011;41(3):588 -91.
8.Sullivan HC, Gerner -Smidt C, Nooka AK, Arthur CM, Thompson L, Mener A, et al. 
Daratum umab (ant i-CD38) induces loss of CD38 on red blood cells. Blood 
2017;129(22):3033 -7.
9.Ramaschi G, Torti M, Festetics ET, Sinigaglia F, Malavasi F, Balduini C. Expressio n of cyclic 
ADP -ribose-synthetizing CD38 mo lecule on human platelet membrane. Blood 
1996;87(6):2308 -13.
10.Sanada C, Xavier -Ferrucio J, Lu YC, Min E, Zhang PX, Zou S, et al. Adult human 
megakaryocyte -erythroid progeni tors are in the CD34+CD38midfraction. Bl ood 
2016;128(7):923 -33.
11.Clemens PL, Yan X, Lokhorst HM, Lonial S, Losic N, Khan I, et al. Pharmacokinet ics of 
Daratum umab Fo llowing Intravenous Infusio n in Relapse d or Refractory  Mul tiple Myelo ma 
After Prior Proteasome Inhibitor and Immuno modulatory  Drug Treatm ent. Clin 
Pharmacokinet 2017;56(8):915-24.
12.Wang X, Dahl M, Nguy en D, Jenks S, Cashman K, Lee FEH, et al. The Anti- CD38 
Monoclonal  Antibody  TAK -079 Deplete s Ant ibody Secreting Cells fro m Normal  and SLE 
Patients [abstract]. Arthritis Rheumatol 2016;68(suppl 10). 2016 ACR/ARHP Annual 
Meet ing, 1085.
13.Guidance for industry : S6 addendum to preclinical safet y evaluat ion of biotechno logy-derived 
pharmaceut icals. US Departm ent of  Heal th and Human Services, Food and Drug 
Administrati on, Center for Drug Evaluat ion and Research (CDER).
14.Regan DM, Markowitz MA. Mit igating the Ant i-CD38 Interference with Serology  Test ing. 
Advancing Transfusio n and Cellular Therapies World wide Associ ation Bullet in #16 -02 
2016:1 -4.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 82of 110
Protocol Incorporating Amendment No 01 19 February 2019
15.Darzal ex (daratum umab) [package insert]. Horsham, PA: Janssen Biotech, Inc.
16.Rituxan (ri tuximab) [package insert]. South San Francisco, CA: Genentech, Inc., 2013.
17.Lee DW, Gardner R, Porter DL, Lo uis CU, Ahmed N, Jensen M, et al. Current concepts in the 
diagnosis and m anagement of cy tokine release syndrome. Blood 2014;124(2):188-95.
18.Darzal ex (daratum umab) [prescribing information]. Horsham, Pennsylvania: Janssen Biotech, 
Inc., 2017.
19.Chari  A, Nahi H, Mateos M, Lokhorst H, Kaufman J, Moreau P, et al. Subcutaneous Deliver y 
of Daratum umab in Pat ients (pts) with Relapsed or Refractory  Mul tiple Myelo ma (RRMM): 
Pavo, an Open- Label , Mul ticenter, Dose Escalat ion Phase 1b Study . Blood (ASH Annual 
Meeting Abstracts) 2017;130(838).
20.Ellis AK, Day  JH. Di agnosis and management of anaphylaxis. CMAJ 2003;169(4):307-11.
21.Delforge M, Ludwig H. How I manage the toxicit ies in myelo ma drugs. Blood (ASH Annual 
Meet ing Abstracts) 2017;129:2359 -67.
22.Sampson HA, Munoz -Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A, et al. 
Second symposium on the definit ion and m anagement of anaphylaxis: summary  
report --Second National Inst itute of Allergy and Infect ious Di sease/Food Allergy and 
Anaphylaxis Network symposi um. J Allergy  Clin Immunol  2006;117(2):391-7.
23.Lieberman P, Kemp SF, Oppenheimer J, Lang DM, Bernstein L, Nicklas RA, et al. The 
diagnosis and m anagement of anaphylaxis: an updated practice parameter. J Allergy  Clin 
Immunol 2005;115(3 Su ppl 2):S483 -523.
24.Richter RJ, Martin TG, Vij R, Cole C, Atanackovic D, Zonder JA, et al. Updated data from a 
phase II dose finding trial o f single agent isatuximab (SAR650984, ant i-CD38+mAB) in 
relapsed/refractory  multiple myelo ma (RRMM). J Clin Onco l 2016;34(15). 8005.
25.Guidance for Clinical Trial Sponsors. Establishment and Operation of Clinical Trial Data 
Moni toring Committees. U.S. Department of Health and Human Services Food and Drug 
Administrati on March 2006. Publicat ion No. OMB Control No. 091 0-0581.
26.Mankarious S, Lee M, Fischer S, Pyun KH, Ochs HD, Oxelius VA, et al. The half -lives of IgG 
subclasses and specific antibodies in pat ients with primary  immunodeficiency  who are 
receiving intravenously  administered immunoglobulin. J Lab Clin Med 1988;112(5):634 -40.
27.Suzuki  T, Ishii -Watabe A, Tada M, Kobay ashi T, Kanayasu- Toyoda T, Kawanishi T, et al. 
Importance of neonatal FcR in regulat ing the serum half -life of therapeutic proteins containing 
the Fc dom ain of human IgG1: a comparat ive study o f the affinit y of mo noclonal antibodies 
and Fc -fusio n proteins to human neonatal FcR. J Immuno l 2010;184(4):1968 -76.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 83of 110
Protocol Incorporating Amendment No 01 19 February 2019
18.0 APPENDICES
Appendix APregnancy and Contraception
Contraception and Pregnancy Avoidance Procedure
Male S ubjects and Their Female Partners
From  signing of informed consent, throughout the duration of the study , and for 90 days or 5 
half-lives after last dose of study  drug, all male subjects who are sexually  active wi th a female 
partner of child- bearing potent ial* must use barrier contraception (eg, condom with spermicidal 
cream  or jelly). In addi tion, they  must be advised not to donate sperm during this period. Wo men 
of child -bearing potential who are partners of male subjects are also advised to use addit ional 
contraception as shown in the list containing highly  effect ive/effect ive contraception found at the 
end of this Appendix. Note the half- life of TAK -079 has not y et been determined. Based on 
conservative informat ion in the literature regarding the half -life of IgG1 immunoglobulins as well 
as other IgG1 human monoclonal ant ibodies [26,27] a conservat ive timeframe to continue 
contraception would be 150 days. 
Female Subjects and Their Male Partners
From  signing of informed consent, throughout the duration of the study , and for 90 days or 5 
half-lives after last dose of study  drug, female subjects of child -bearing potential* who are 
sexually  active wit h a no nsterilized male partner** must use a highly effect ive/effect ive method of 
contraception (fro m the list that fo llows). As the half -life of TAK -079 has not yet been determined, 
based on conservat ive informat ion in the literature regarding the half -life o f IgG1 
immunogl obulins as well a s other IgG1 human monoclonal antibodies [Mankarious et al 1088; 
Suzuki  et al  2019], a conservat ive timeframe to cont inue contraception would be 150 days.
In addit ion, they  must be advised not to donate ova during this period.
Definitions and Procedures fo
r Contraception and Pregnancy Avoidance
The follow ing definitions apply for contraception and pregnancy avoidance procedures.
* A woman is considered to be of child -bearing potent ial (ie, fertile) fo llowing menarche and until 
beco ming postmenopausal unless permanent ly sterile. Permanent sterilizat ion methods include 
hysterectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 
months wit hout an alternat ive medical cause and a high FSH concentration (>40 IU/L) before any 
study medicat ion is administered. However, in the absence of 12 months of amenorrhea, a single 
FSH m easurement is insufficient.
** Sterilized males should have undergone bilateral vasectomy at least 1 y ear before entering the 
study  and able to provi de docum entation of  the absence of sperm in the ejaculate or bilateral 
orchi ectomy .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 84of 110
Protocol Incorporating Amendment No 01 19 February 2019
The follow ing procedures apply for contraception and pregnancy avoidance.
Highly effective m ethods of contraception are defined as “those, alone or in combinat ion, that 1.
resul t in a l ow failure rate (i e, less than 1% failure rate per y ear when used consistent ly and 
correctly ). In this study , the only  acceptable methods of contraception are: 
Nonhorm onal methods: 
–Intrauterine device (IUD).
–Bilateral tubal occlusio n.
–Vasectomized partner (provi ded that partner i s the sole sexual partner of the trial 
participant and that the vasectomized partner has received medical assessment of the 
surgi cal success).
–True sexual abst inence, only if this is in line wit h the preferred and usual life style o f the 
subject. Periodic abst inence (eg, calendar, ovulat ion, symptothermal, and 
postovulat ion methods), withdrawal, spermicides only, and lactational amenorrhea are 
not acceptable methods of contraception.
Horm onal methods: Horm onal contracepti on ma y be suscept ible to interaction with the 
investigat ive co mpound, comparator, or concomitant medicat ions, which may reduce the 
efficacy o f the contraception method.
–Combined (estrogen and progestogen) hormonal contraception associated with 
inhibit ion of ovulation initiated at least 3 months prior to the first dose of study  drug 
OR combined with a barrier method (male condo m, female condom, or diaphragm) if 
for shorter durati on unt il she has been on a contraceptive for 3 months;
Oral †.
Intravaginal †(eg, ri ng).
Transdermal †.
–Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation 
initiated at least 3 months before the first dose of study  drug OR combined with a 
barrier m ethod (m ale condo m, female condo m, or di aphragm ) until  she has b een on a 
contraceptive for 3 months;
Oral †.
Injectable.
Implantable.
Other effect ive methods of contraception (there may be a higher than 1% failure rate) are: 2.
Doubl e-barrier method (contraceptive sponge, diaphragm or cervical cap wit h spermicidal 
jellie s or creams PLUS male condom).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 85of 110
Protocol Incorporating Amendment No 01 19 February 2019
Progestogen only hormonal contraception, where inhibit ion of ovulat ion is not the primary 
mode of act ion PLUS condom wit h or without spermicide.
Unacceptable methods of contraception are:3.
Periodic abst inence (eg, calendar, ov ulation, symptothermal, postovulat ion methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Use of female and male condoms together.
Cap/di aphragm/sponge wi thout spermicide and wit hout condom.
Sexual abst inence is NOT an acceptable method of contraception.
Subjects will be provided with information on highly effect ive/effect ive methods of 4.
contraception as part of the subject informed consent process and will be asked to sign a 
consent form stating that they  understand the requirements for avoi dance of pregnancy, 
donati on of  ova, (and sperm donat ion) during the course of the study .
During the study , regul ar serum /or urine hCG pregnancy tests will be performed only  for 5.
wom en of child -bearing potenti al, and all subjects (male and female) will rece ive continued 
guidance wi th respect to the avoidance of pregnancy  and sperm  donat ion as part of the study  
procedures. Such guidance should include a reminder of the fo llowing:
a)Contraceptive requirements of the study
b)Reasons for use of barrier methods (ie, condom ) in males wi th pregnant partners
c)Assessment of subject compliance through such questions as:
i.Have you used the contraception consistent ly and correctly since the last visit ?
ii.Have y ou forgotten to use contraception since the last visit ?
iii.Are y our m enses late (even in women with irregular or infrequent menstrual cycles, a 
pregnancy test must be performed if the answer is “yes”)
iv.Is there a chance you could be pregnant ?
In addition, negat ive pregnancy results must be confirmed in female subjects of child -bearing 6.
potenti al, during the foll owing timeframes: 
a)Screening and baseline: 
i.During screening; a negat ive serum pregnancy  test (hCG < 5 mIU/mL ).
ii.Before first dose of investigational drug (within 24 hours); a negative urine pregnancy 
test (wi th sensit ivity <50 m IU/mL). 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 86of 110
Protocol Incorporating Amendment No 01 19 February 2019
Note: Before administration of the first dose of investigational drug, the subject must 
confirm menses within the past month before dosing (ie, no delayed menses).
b)Study  dosing peri od: urine screening
i.Prior to each study  dosing day .
c)At any time point during study  enrollment: serum  screening
i.If a menstrual period is delayed. 
ii.On request by  an IRB or if required by  local regulati ons.
If any subject is found to be pregnant during the study , she shoul d be withdrawn and any  
sponsor -supplied drug should be immediately discontinued. In addit ion, any pregnancies in the 
partner of a male subject during the study or for 90 days after the last dose should also be recorded 
following authori zation from the subject’s partner. 
If the female subject agrees to the primary care physician being informed, the invest igator should 
notify the primary  care physician that the subject was participat ing in a clinical study at the time 
she became pregnant and provide details of th e study  drug the subject received (blinded or 
unblinded, as applicable).
All pregnancies, including female partners of male subjects, in subjects on active study  drug will  
be fo llowed up to final outcome, using the pregnancy form. The outcome, including an y premature 
termination, must be reported to the sponsor. An evaluat ion after the birth o f the child will also be 
conducted.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 87of 110
Protocol Incorporating Amendment No 01 19 February 2019
Appendix B Clinical Signs and Symptoms of Cytokine Release Syndrome
Organ System Symptoms
Constitut ional Fever with or without rigors, malaise, fatigue, anorexia, myalgias, arthalgias, nausea, 
vomiting, headache
Skin Rash
Gastrointestinal Nausea, vomiting, diarrhea
Respiratory Tachy pnea, hy poxemia
Cardiovascular Tachycardia, widened pulse pressure, hypotension, increased cardiac output (early), 
potentially diminished cardiac output (late)
Coagulation Elevated D -dimer, hypofibrinogenemia with or without bleeding
Renal Azotemia
Hepatic Transaminitis, hyperbilirubinemia
Neurologic Headache, mental s tatus changes, confusion, delirium, word -finding difficulty or frank 
aphasia, hallucinations, tremor, dysmetria, altered gait, seizures 
Source: Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and 
manage ment of cytokine release syndrome. Blood 2014;124(2):188 -95.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 88of 110
Protocol Incorporating Amendment No 01 19 February 2019
Appendix CGrading System for Cytokine Release Syndrome
Grade Toxicity
Grade 1 Symptoms are not life threatening and require symptomatic treatment only (eg, fever,
nausea, fatigue, headache, myalgias, malaise)
Grade 2 Symptoms require and respond to moderate intervention
Oxygen requirement <40% or
Hypotension responsive to fluids or low dose of one vasopressor or 
Grade 2 organ toxicity
Grade 3 Symptoms require an d respond to aggressive intervention
Oxygen requirement ≥40% or
Hypotension requiring high dose or multiple vasopressors or
Grade 3 organ toxicity or 
Grade 4 transaminitis
Grade 4 Life-threatening sy mptoms
Requirements for ventilator support or
Grade 4 o rgan toxicity (excluding transaminitis)
Grade 5 Death
Source: Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and 
management of cytokine release syndrome. Blood 2014;124(2):188 -95.
Grades 2 to 4 refer to the CTCAE v4.03 grading.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 89of 110
Protocol Incorporating Amendment No 01 19 February 2019
Appendix DResponsibilities of the Investigator
Clinical research studies sponsored by  the Sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imp osed on invest igators by  the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff that will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duties and funct ions, the invest igator/inst itution shoul d ensure that this individual 
or party  is qualified to perform those trial -related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions performed and any 
data generated.
4.Ensure that study -related procedures, including study -specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects before the receipt of written 
approval  from relevant governin g bodi es/authori ties.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 CFR Part 56, ICH, and lo cal regulatory  requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to patients. Make at lea st yearly  reports on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
8.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
9.Obtain valid info rmed consent from  each subject who participates in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each ICF should contain a subject authorizat ion secti on that 
describes the uses and disclosures of a subject’s personal informat ion (including personal 
healt h informat ion) that will take place in connect ion with the study. If an ICF does not include 
such a subject authorizat ion, then the investigator must ob tain a separate subject authorizatio n 
form from each subject or the subject’s legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, and laboratory  resul ts, and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 90of 110
Protocol Incorporating Amendment No 01 19 February 2019
contact and receive writt en approval fro m the sponsor before disposing o f any such 
docum ents.
11.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the Sponsor. 
13.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 91of 110
Protocol Incorporating Amendment No 01 19 February 2019
Appendix EInvestigator Conse nt to the Use of Personal Information 
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferr ed to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing par tners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suita bility of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medicati ons used in other clinical studies that may contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates , and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Taked a 
and other parties for the purposes described above.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 92of 110
Protocol Incorporating Amendment No 01 19 February 2019
Appendix FElements of the Subject’s Informed Consent
In seeking informed consent, the fo llowing information shall be provided to each subject:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of pat ients involved in the study .
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatment.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A statement describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By signing a written ICF, the subject or the subject’s 
legally acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an e xplanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if injury  occurs and, if 
so, what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , to the subject for parti cipat ing in the study.
18.An explanat ion of whom to contact for answers to pertinent questions about the research 
(invest igator), subject’s rights, and IRB/I EC and who m to contact i n the event of a 
research -related inj ury to the subject.
19.A statement that participation is vo luntary, that refusal to participate will invo lve no penalt y or 
loss of benefit s to whi ch the subject otherwise is ent itled, and that the subject or the subject’s 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 93of 110
Protocol Incorporating Amendment No 01 19 February 2019
legally acceptable representative may discont inue participat ion at any  time wi thout penal ty or 
loss of benefit s to whi ch the subject is otherwise ent itled.
20.The consequences of a subject’s decisio n to wi thdraw from  the research and procedures for 
orderly terminat ion of part icipation by the subject.
21.A statement that the subject or the subject’s legally acceptable representative will be informed 
in a timely  manner if informat ion beco mes available that may be relevant to the subject’s 
willingness to continue participat ion in the study .
22.The foreseeable circumstances or reasons under which the subject’s participat ion in the study  
may be terminated.
23.A wr itten subject authorization (eit her contained within the informed consent form or provide d 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health informat ion) for 
purposes of conduct ing the study. The subject authorizat ion must con tain the fo llowing 
statements regarding the uses and disclosures of the subject’s personal informat ion:
That personal informat ion (including personal health informat ion) may be processed by or 
transferred to other parties in other countries for clinical re search and safet y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and licensing 
partners; (3) regulatory  agencies and other hea lth authorities; and (4) IRBs/IECs;
It is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
patients the sam e level  of protecti on as the data protecti on laws wi thin this country; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
That personal informat ion (including personal h ealth information) may  be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  medicat ion(s), studying other therapies for patients, 
developing a better understanding of disease , and improving the efficiency of future 
clinical studies;
That patients agree not to restrict the use and disclosure of their personal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
That the subject’s ident ity will remain confidential in the event that study  resul ts are 
published.
24.Female pat ients of child -bearing potenti al (eg, nonsterilized, premenopausal female pat ients) 
who are sexually  active m ust use highly  effect ive contraception (as defined in the informed 
consent) from signing the informed consent through 90 days or 5 half -lives of study  drug, 
whichever i s longer, after the l ast dose of study drug. Regular pregnancy  tests will  be 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 94of 110
Protocol Incorporating Amendment No 01 19 February 2019
perform ed throughout the study for all female pat ients of child -bearing potential. If a subject is 
found to be pregnant during study , study  drug wil l be discont inued and the invest igator will 
offer the subject the choice to receive unblinded treatment informat ion. 
25.Male patients must use highly effect ive contraception (as defined in the informed consent) 
from signing the informed consent throughout th e duration of the study  and f or 90 day s after 
the last dose of study  drug. If the partner or wife of the subject is found to be pregnant during 
the study , the invest igator will o ffer the subject the cho ice to receive unblinded treatment 
inform ation. 
26.A statement that clinical trial informat ion fro m this trial will be publicly disclo sed in a publicly 
accessible website, such as ClinicalTrials.gov.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 95of 110
Protocol Incorporating Amendment No 01 19 February 2019
Appendix GDose Modeling of TAK -079
The select ion of doses and the frequency of administrati on of  TAK -079 f or the TAK -079-2001 
study  are based on the following: (1) a comprehensive review and analysis o f data derived from the 
dosing of healt hy subjects with TAK -079 ( TAK -079-101
); (2) repeat dosing o f monkeys wit h 
TAK -079 ( TAK -079-1001
5, TAK -079- 1018, and TAK - 079-10019 ); and, (3) data derived from 
repeat dosing of pat ients with multiple myel oma with daratum umab (Darzalex), a related 
anti-CD38 cy tolytic ant ibody  [11].
A semimechanist ic population PK/PD model for TAK -079 wi th target- mediated drug disposit ion, 
incorporated the exist ing knowledge ment ioned above. The model was subsequent ly used t o 
conduct simulat ions of different doses to project human PK and est imate changes in PB, NK cells, 
B cells, and T cells (as outlined in Figure 1).
The 45 mg dose for the init ial dosing cohort (ie, Cohort A) is selected based on the favorable safet y 
profile and therapeutic target effect (ie, a sustained reduction of PBs) observed after a 0.6 mg/kg 
dose was administered to healt hy subjects (Study  TAK -079- 101). A single SC dose of 0.6 mg/kg 
TAK -079 reduced the level of PBs in peripheral blood >90% and NK cells >80% wi thout 
comparable reductions in mo nocy tes and B and T cells. Levels of PBs and NK cells recovered to 
50% of baseline levels 21 days after administration, on average (Figure 2). Two subsequent dosing 
cohorts are planned at doses of 90 mg (2
-fold increase fro m the first dose cohort) and 135 mg (a 
50% increase fro m the previous cohort), keeping in mind a balance of benefit -risk.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 96of 110
Protocol Incorporating Amendment No 01 19 February 2019
Figure 1 Levels of Plasmablasts, Monocytes, and B, T, and NK Cells in Peripheral 
Blood of Healthy Subjects After a Single Admi nistration of Placebo or 
0.6mg/kg TAK -079 on Day 0
Source: TAK -079- 101 Report
Abbreviation: NK, natural killer; SC, subcutaneous.
Graph indicates change of immuno -inflammatory cells following a single SC dose of 0.1 mg/kg, 0.3 mg/kg, or 
0.6mg/kg of TAK -079 or matching placebo; medians indicated by solid lines; 95% CI indicated by associated 
shading.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 97of 110
Protocol Incorporating Amendment No 01 19 February 2019
Figure 2 Summary of Dose Modeling Overview by Dose
Predicted plasmablast % change from baseline 
following a single TAK -079 SC dose of 45 mg, 90 mg, 
and 13 5 mgPredicted T -cell levels change from baseline following 
a single TAK -079 SC dose of 45 mg, 90 mg, and 135 mg
A. Plasmablasts following 45 mg SC Dose aD. T cell levels following 45 mg SC dose a
B. Plasmablasts following 90 mg SC dose aE. T cell levels following 90 mg SC dose a
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 99of 110
Protocol Incorporating Amendment No 01 19 February 2019
Appendix HDetailed Description of Amendment to Text 
The primary sect ions of the protocol affected by the changes in Amendment 01 are indicated. The 
corresponding text has been revised throughout the protocol. 
Change 1:Clarificat ion that the assessment of systemic lupus ery thematosus ant ibodies (Ab) is 
expected at baseline.
The primary  change occurs in Table 3.aSchedule of Events
Descript ion of 
change: In the row SLE Ab , in the cell spanning Screening column, X was added.
Rationale for Change : Table 3a in original protocol did not align with SLE Ab timings in origina l 
protocol .
Change 2:Clarificat ion that no dosing criteria assessments are to be conducted as part of 
screening.
The p rimary  change occurs in Table 3.aSchedule of Events
Descript ion of 
Change: In the row Dosing criteria assessment , in the cell spanning Screening column, 
Xwas removed, wi th footnote o.
Rationale for Change: Table 3.ain original  protocol  did not align with dosing criteria assessment
timings in original protocol.
Change 3:Removal of redundant RNA sampling schedule in Table 3.a.
The primary  change occurs in Table 3.aSchedule of Events
Descript ion of 
Change: The row RNA , was removed.
Rationale for Change : RNA assessment timings are adequately  covered in other areas of the 
protocol , rem oval reduced redundancy , and improving protocol  clari ty.
Change 4: Addit ion of a one -day window (+/ -1 day) for visit s: HV7, HV8 and HV9, has been 
added for cons istency wit h other vi sits.
The primary  change occurs in Table 3.aSchedule of Events
Descript ion 
of Change: In the header cells for columns rows HV7, HV8 andHV9, (+/-1 day) has been added to 
each header cell.
Rationale for Change : All HV visits have a visit window allowance of +/ -1 day . Adding the +/ -
1 day  allowance f or HV7, HV8, and HV9 in Table 3.a, provides the necessary consistency .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 100of 110
Protocol Incorporating Amendment No 01 19 February 2019
Chang e 5: Removal of details for urine sample co llection.
The primary  change occurs in Table 3.aSchedule of Events footnote k
Initial 
wording:kUrinalysis, including  and nitrates, will be performed by 
central  laboratory  1 week before dosing; addit ional prot ein and nitrate assessments are 
to be performed by local laboratory (ie, dipst ick) on study dosing days, before dosing; 
abnorm al findings by  local laboratory  assessment must be confirmed by central 
laboratory  evaluat ion. Sam ples m ust be first morning urine collected by pat ients in 
specimen containers provided by the study  site. Further detail  is provided in 
Secti on9.2.8.3 . 
Amended 
or new 
wording:kUrinalysis, including  and nitrates, will be performed by 
central  laboratory  1 week before dosing; addit ional protein and nitrate assessments are 
to be performed by local laboratory (ie, dipst ick) on study dosing days, before d osing; 
abnorm al findings by  local laboratory  assessment must be confirmed by central 
laboratory  evaluat ion. Samples m ust be first morning urine co llected by pat ients in 
specimen containers provided by the study site. Further detail is provided in 
Secti on9.2.8.3 . 
Rationale for Change: Instructions wit hin protocol are unnecessary  as such details will be 
provi ded in site trainings and associated stu dydocum ents f or the si te staff 
Change 6:Clarificat ion of T -cell safet y parameters as they  pertain to dosing criteria. This 
clarificati on takes into consi derat ion the natural history  of SLE on background therapy , the 
patient’s T-cell baseline values, as well as changes fro m baseline that would warrant the 
continuat ion or hol ding of a dose of TAK -079.
The primary  change occurs i n Table 6.bSummary of Dosing Criteria
Initial 
wording:In the row T-cells, in the cell spanning Continuing Dosing column, ori ginal 
text read, “ T cells ≥500 cells/uL”
In the row T-cells, in the cell spanning Dosing Ho ld column, original text read, 
“Tcells <500 cells/uL”
Amended 
or new 
wording:In the row T-cells, in the cell spanning Continuing Dosing column, new text 
was added to exist ing text: “NOTE: Dosing may continue in instances of 
T cells <500 cells/uL if CD3 + cell count is ≥70% of the baseline level” .
In the row T- cells, in the cell spanning Dosing Hold column, text was 
amended : “CD3+ cells count <500 cells/uL and is < 70% of baseline CD3 + 
cell count level .”
The fo llowing sect ions also contain this change: No other areas of the protocol are impacted by 
this change .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 101of 110
Protocol Incorporating Amendment No 01 19 February 2019
Rationale for Change: This clarificat ion incorporates considerat ion of the natural history of SLE 
on background therapy , the pati ent’s T -cell baseline values, as well as changes fro m baseline that 
woul d warrant the continuat ion or hol ding of a dose of TAK -079. Thi s clarificat ion now
incorporates all available T -cell count information into the dosing decisio ns.
Change 7: Changes to dosing criteria in the event of infusio n related reacti on, to better align 
actions wi th the appropri ate grading cr iteria. Grade 2 or higher reactions st ill require dose 
discontinuat ion.
The primary  change occurs in Table 6.bSummary of Dosing Criteria
Initial 
wording:In the row TAK-079- related infusion reaction, in the cell spanning Continuing Dosing 
column, ori ginal text read, “ Grade 1 ”.
Amended 
or new 
wording:In the row TAK-079- related infusion reaction, in the cell spanning Continuing Dosing 
column, new text was added to exist ing text: “≥ Grade 1 with symptom atic treatment 
allowed in accordance with Appendix C. NOTE: Dosing may resume after symptoms 
have reso lvedf “
The fo llowing sect ions also contain this change: No other areas of the protocol are impacted by 
this change .
Rationale for Change: Added statement allows for alignment with referenced grading criteria.
Change 8: Clarificat ion of dosing criteria in the event of hypersensit ivity-related events, to better 
align with the CTCAE criteria for allergic react ions, as originally intended. Any  symptom  ofan 
anaphylactic reaction cont inues to require TAK -079 discont inuat ion.
The primary  change occurs in Table 6.bSummary of Dosing Criteria
Initial 
wording:1.Under the column, Laboratory Investigations , original  text in cell 
“Hypersensit ivity”,
Amended or 
new wording:1.Under the column, Laboratory Investigations , new text added to cell 
“Hypersensit ivity”, is as fo llows “(allergic react ion or anaphylaxis) ”.
2.In the row Hypersensitivity” , in the cell spanning Continuing Dosing 
column, new text was added “≤Grade 2 In accordance wit h NCI CTCAE, 
versio n 4.03 grading for allergic reactions which respond promptly to 
symptom atic measures ”.
3.In the row Hypersensitivity” , in the cell spanning Dose Hold column, the 
following text was deleted, “Grade 1 as per NCI CTCAE grading for 
allergic reactions .Hold and reassess as per protocol t imings for next dose”
4.In the row Hypersensitivity” , in the cell spanning Dose Discontinuation 
column, thetext was amended as fo llows, “ ≥Grade 3c2 In accordance 
with NCI CTCAE (version 4.03) grading for allergic react ion
oranysigns or symptoms of an anaphylact ic react ion.”
5.In the row Hypersensitivity” , in the cell spanning Dose Discontinuation 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 102of 110
Protocol Incorporating Amendment No 01 19 February 2019
column, a citation to the fo llowing reference was added: 
Regan DM, Markowitz MA. Mit igating the Anti -CD38 Interference 
with Serol ogy Testing. Advancing Transfusio n and Cellular 
Therapies World wide Associat ion Bullet in #16 -02 2016:1 -4.
6.Footnote c, text was amended as fo llows: “Laboratory  grading, allergic 
reactions, and infection grading is based on NCI CTCAE v 3.0.4.03. ”
The fo llowing sections also contain this change: No other areas of the protocol are impacted by 
this change .
Rationale for Change: Changes were made to better align wit h the CTCAE criteria for allergic 
reacti ons as ori ginally intended. No changes were made to anaphylact ic reactions .
Change 9: Clarificat ion that Commo n Termino logy Criteria for Adverse Events versio n 4.03 must 
be used in the study .
The primary  change occurs in Table 6.bSummary of Dosing Criteria .
Added text : NCI CTCAE, version 4.03
Rationale for Change: To ensure consistent use of NCI CTCAE versio n as intended.
Change 10: Clarificat ion of excluded and dose limited conco mitant m edicat ions
The primary  chan ge occurs in Secti on 7.3in Table 7.aand Table 7.b.
Initial 
wording:Table 7.aUnder the column, Exclusion Criteria , in cell spanning 
Immunosuppressant regimen original text was“To incl ude 
calcineurin -inhibitors (eg, systemic cy closporine and tacrolimus), 
leflunomide, to be excluded throughout study  participation”
Table 7.bUnder the column Dosing Criteria , in the cell spanning 
Immunosuppressants , original  text was “ Regimens consi sting of ≥ 2agents 
while on study  (not applicable to topical agents; see dose rest rictions outlined 
in Table 7.a”
Table 7.bUnder the column Dosing Criteria, in the cell spanning 
Corticosteriods , original  text was “Stable dosing equivalent to ≤20mg/day o f 
oral predi solonemaintained for ≥28days prior to the first dose of TAK -079 or 
matching placebo. ”
Amended 
or new 
wording:Table 7.aUnder the column, Exclusion Criteria , in cell  spanning 
Immunosuppressant regimen new text added to origina ltext, “ To include 
calcineurin -inhibitors (eg, sys temic cy closporine and tacrolimus), 
leflunomide, to be excluded throughout study  partici pation. Must be 
discontinued at least 3 months before screening visit. ”
Table 7.bUnder the column Dosing Criteria , in the cell spanning 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 103of 110
Protocol Incorporating Amendment No 01 19 February 2019
Immunosuppressants , amended text i s “Regimens consist ing of <2agents
while on study  (not applicable to topical agents; see dose restrict ions outlined 
in Table 7.a”
Table 7.bUnder the column Dosing Criteria, in the cell spanning 
Corticosteriods , amended text is“Stabl e dosing equivalent to ≤20mg/day o f 
oral prednisone prediso lonemaintained for ≥28days prior to the first dose o f 
TAK -079 or m atching placebo. ”
The fo llowing sect ions also contain this change: No other areas of the protocol are impacted by 
thischange .
Rationale for Change: Statement regarding timeframe for discontinuation of 
immunosuppressants was added for consistency. Other change s were corrections of typographical 
error sin the original protocol.
Change 11: The addit ion of  a protocol  subsect ion to provi de clarificat ion regarding potential 
interference wi th serol ogical testing.
The primary  change occurs in Section 6.4
Added text :6.4.3 Interference with Serological Testing
Anti- CD38 monoclonal antibodies have been reported to bind to CD38 on red 
blood cells (RBCs) and results in a positive indirect coombs test, which may 
persist for up to 6 months. The determination of a patient’s ABO and Rh blood 
type are not impacted, but the RBC binding may mask detection of antibodies to 
minor antigens in the patient’s serum [14,15].It is possible TAK -079 may affect 
the results of these blood tests, this is being evaluated. Until those tests are 
known, it is re commended that baseline type and serological screening be 
established before starting TAK -079. Patients should keep these results in case 
future transfusions are needed. Blood transfusion centers should also be 
informed of this interference with serologica l testing as necessary. 
Rationale for Change: The impact that TAK -079 may have on minor ant ibodies is st ill to be 
determined through ongoing analysis. The newly added section provides clarit y on thi s potenti al 
impact, and the importance of establishing b aseline bl ood and serol ogy levels at screening, as a 
precauti onary  safety  measure shoul d future transfusions be required while the patient is on study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 104of 110
Protocol Incorporating Amendment No 01 19 February 2019
Change 12: Clarificat ions m ade regarding the management of hypersensit ivity react ions to better 
align with the CTCAE criteria for allergic react ions, as or iginally  intended.
The primary  change occurs in Section 6.5.1.1
Initial 
wording:Grade 1 :
Study  Management: Hold further TAK -079 dosing until symptoms resolve. Resume 
dose of TAK -079 at sam e dose l evel at the time of symptom reso lution with 
appropriate prophylact ic medical care.
Patient Support: Provide symptomat ic treatment, to include epinephrine as needed.
Grade 2 :
Study  Management: Discont inue study dosing and advance to the safet y follow-up 
period of  the study .
Patient Support: For anaphylaxis, provide symptomat ic treatment, to include 
epinephrine. 
Grade 3 or Greater: (symptom atic bronchospasm with or with out urti caria, 
angioedema, hy potensi on). 
Study  Management : Patients are to discont inue study dosing and advance to the safet y 
follow-up period of the study .
Patient Support : Provide symptomat ic treatment, including epinephrine, unt il 
symptoms resolve. 
Local inject ion site abnormalit ies have not been observed in mo nkey and rat 
nonclinical studies after SC and/or IV administration of TAK -079. In the clinical 
study  of healt hy subjects (TAK -079- 101), mild injection site AEs were reported; most
were Grade 1 an d included primarily ery thema or tenderness. All injection react ions 
resolved wit hin a few days.
Grade 3 or Greater: (symptom atic bronchospasm with or without urticaria, 
angioedema, hy potensi on). 
Study  Management : Patients are to discont inue study dosing and advance to the safet y 
follow-up period of the study .
Patient Support : Provide symptomat ic treatment, including epinephrine, unt il 
symptoms resolve. 
Amended 
or new 
wording:Grade 1 
a)Study Management: 
Hold further TAK -079 dosing until symptoms resolve. Resume dose of 
TAK 079 at sam e dose l evel at the time of symptom resolution wit h 
appropriate prophylact ic medical care .If the full dose of TAK -079 has not 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 105of 110
Protocol Incorporating Amendment No 01 19 February 2019
yet been administered, hold dosing until symptoms resolve, at which time 
the remainder of T AK-079 dose may be administered.
b)Patient Support
Provi de symptom atic treatment, to include epinephrine as needed .Monitor 
closely until resolution of symptoms. 
Grade 2 
c)Study Management: 
Discontinue study  dosing and advance to the safety  followup peri od of  the 
study .If the full dose of TAK -079 has not yet been administered, hold 
dosing until symptoms resolve, at which time the remainder of TAK -079 
dose may be administered. 
d)Patient Support
For anaphylaxis, provide symptomat ic treatment, to include epine phrine.
Administer appropriate symptomatic and prophylactic 
medical care; consider post -injection medications as 
outlined in Section 6.2.2.
For allergic reaction, provide symptomatic treatment (e.g. 
antihistimines, nonsteroidal anti -inflammatory drug s, 
narcotics, epinephrine) as medically appropriate and 
consider post -infection medications (as per Section 6.2.2).
Grade 3 or Greater: (symptom atic bronchospasm with or without urticaria, 
angioedema, hy potensi on). 
a)Study Manag ement : 
Patients are to di scont inue study  dosing and advance to the 
safet y follow-up peri od of  the study .
b)Patient Support :
Provi de symptom atic treatment, including epinephrine, until 
symptoms resolve. 
Consider hospitalization as appropriate.
The following sect ions also contain this change: No other areas of the protocol are impacted by 
this change .
Rationale for Change: Revised text provides clarificat ion for appropriate symptom management
to better align with appropriate toxicit y grading criteri a gui dance, while provi ding pati ents the 
opportunit y to continue study  dosing if and when symptoms should resolve.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 106of 110
Protocol Incorporating Amendment No 01 19 February 2019
Change 13: Removal of any reference to an unblinded pharmacist.
The primary  change occurs in Section 8.1.3
Initial 
wording:The assignment of study  patients to one of two study  arms, wi thin each cohort, is 
maintained through a blinded randomizat ion schedule, availabl e to the study  site 
pharmacist, and in instances of medical emergencies, to the principal invest igator. 
Details on maintaining the study  blind, and unblinding procedures are outlined in 
Secti on8.1.5 .
Amended 
or new 
wording:The assignment of study  patients to one of two study  arms, wi thin each cohort, is 
maintained through a blinded randomizat ion schedule, available , to the study  site 
pharmacist, andin instances of m edical  emergencies, to the principal invest igator. 
Otherwise site staff , will remain blinded through the conduct of the study . Details 
on maintaining the study  blind, and unblinding procedures are outlined in 
Secti on8.1.5 .
The fo llowing sect ions also contain this change: Section 8.1.5 , Secti on 9.1.2 , and Section 9.1.3
Rationale for Change: Pharmacist is not unblinded in this study
Change 14: Clarificat ion that ECGs are to be read locally, to include readings o f triplicate 
electrocardi ogram s for saf ety assessments. Otherwise, triplicate ECGs will be submitted for 
subsequent central  reading at a future time.
The primary  change occurs in Section 9.2.6
Initial 
wording:A single 12- lead ECG is to be collected at the screening visit (for assessment of 
eligibilit y)and at the end of safet y follow-up visit, and will be read locally. 
Triplicate 12 -lead ECGs, obtained before each study  dose, are to be collected just 
before PK sampling, during timeframes outlined in Table 3.aand Table 3.b. Triplicate 
ECGs will be read centrally. 
When the timing of the triplicate and single (safet y) ECGs coincide, the site can use 
the triplicate ECG collection for the safet y evaluat ion. 
Each ECG recording s hould be performed according to standard institutional pract ice. 
It is recommended that patients refrain fro m eating or limi t themselves to bland food 
for 1hour before dosing and for 1 hour before each scheduled triplicate E CG 
measurement. Each ECG is recorded electronically, interpreted by  aqualified person,
and transmitted to a central vendor for storage .
NOTE: Any  ECG finding that i s judged by  the investi gator as clinically  significant 
(except at the screen ing visit) i s consi dered a TEAE; as such clinically significant 
findings are to be recorded on the source documentation and in the eCRF, and undergo 
continued mo nitoring as described in Sect ion10.2.5.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 107of 110
Protocol Incorporating Amendment No 01 19 February 2019
Amended 
or new 
wording:Each ECG recording should be performed according to standard institutional pract ice.
All study  ECGs, to include triplicate ECGs, are interpreted by a qualified person (ie, 
read locally). Fur ther, triplicate 12 -lead ECGs are recorded electronically and are to be 
submitted to a central vendor for storage and for future analysis. 
ECGs wi th clinically significant findings, as judged by the invest igator , are to be 
considered a TEAE; (except for E CGs obtained as part of the screening) visit which 
woul d be considered part of medical history ). Clinically significant findings are to be 
recorded on the source documentation and in the eCRF, and undergo continued 
monitoring as described in Sect ion 10.2.5
A single 12- lead ECG is to be collected at the screening visit (for assessment of 
eligibilit y) and at the end of safet y follow-up visit , and will be read locally . 
Triplicate 12 -lead ECGs, obtained before each study  dose, are to be collected just 
before PK sampling, during t imeframes outlined in Table 3.a and Table 3.b. Triplicate 
ECGs will be read stored centrally for future analysis . 
When the timing of the triplic ate and single (safet y) ECGs coincide, the site can use 
the triplicate ECG collection for the safet y evaluat ion.
Each ECG recording should be performed according to standard institutional pract ice. 
It is recommended that patients refrain fro m eating or limit themselves to bland food 
for 1 hour before dosing and for 1 hour before each scheduled triplicate ECG 
measurement. Each ECG is recorded electronically, interpreted by  aqualified person,
and transmitted to a central vendor for storage.
NOTE: Any  ECG finding that is judged by  the investi gator as clinically  significant 
(except at the screening visit) is considered a TEAE; as such clinically significant 
findings are to be recorded on the source documentation and in the eCRF, and undergo 
continued mo nitoring as described in Sect ion10.2.5.
Rationale for Change: Addit ional text has been added to alleviate and avo id confusio n regarding 
central  reads, which will be co nducted later in the study; and, to clarify that all ECG (both those 
obtain in single and triplicate) must be read locally.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 108of 110
Protocol Incorporating Amendment No 01 19 February 2019
Change 15: Clarificat ion of Coombs testing to be analyzed by local labs; wit h further clarificat ion 
that all other laboratory  tests, unl ess otherwise noted, should be submitted for central analysis.
The primary  change occurs in Section 9.2.8 .
Initial 
wording:Unless otherwise stated in the protocol, a ll laboratory  samples are to be sent to the 
study  central laboratory for analysis, under the condit ions for handling and shipping as 
outlined in the study laboratory  manual.
Amended 
or new 
wording:Unless otherwise stated in the protocol, all laboratory  samples, with except ion to 
Coombs tests , are to be sent to the study central laboratory for analysis, under the 
condi tions for handling and shipping as outlined in the study  laboratory  manual . 
Coombs test will be done locally .
The fo llowing sect ions also contain this change: No other areas of the protocol are impacted by 
this change.
Rationale for Change: Central  lab vendor does not perform Coombs testing, so test needs to be 
completed by  local lab.
Change 16: Adjustments to pregnancy test met hodol ogy during screening and just prior to the 
first dose of TAK -079, though 2 negative pregnancy  tests are still needed prior to dosing. Details 
about the duration of continued contraception after the last dose of study  medicat ion have been 
added.
The primary  change occurs in Section 9.2.9.2
Initial 
wording:Women of child- bearing potenti al must have pregnancy testing completed in 
accordance to the timings outlined as fo llows: 
Before Initial Study Dosing : Two negative serum pregnancy tests (human 
chori onic gonadotropin [hCG] <5 m IU/mL) to include: 
–Screening period (within 10 to 14 days before the start of study drug) .
–Baseline (within 24 hours before the start of study  drug).
Amended 
or new 
wording:Women of child- bearing potenti al must have pregnancy testing completed in 
accordance to the timings outlined as fo llows: 
Before Initial Study Dosing : Two
–Screening period: a negative serum pregnancy  tests (human chori onic 
gonadotr opin [hCG] <5 mIU/mL) to include: 
1. Screening period (within 10 to 14 days before the start of study  drug).
–Baseline (within 24 hours before the start of study  drug) a negat ive urine 
pregnancy test with a sensit ivity of at least 50 mIU/mL. If the urine test is 
indeterminate, a serum pregnancy test is mandatory .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 109of 110
Protocol Incorporating Amendment No 01 19 February 2019
The fo llowing sect ions also contain this change: Table 3.a, footnote j and Appendix A
Rationale for Change: 
Changes to Pregnancy Testing Criteria: To reduce the need for blood draws within study , while 
maintaining appropriate measures for pregnancy assessments .
Changes to Barrier Contraception After Last Dose On -Study : Change made to provide 
specific detail about suggested duration of contraception after last dose on study drug and r ationale 
for the durati on recommended.
Change 17: Remova l of British Isl es Lupus Assessment Group assessments and all associated 
trainings and site/study  activit ies.
The primary  change occurs in Section 9.3.4
Deleted 
Text 9.3.4.2BILAG 2004 Index
All invest igative site personnel performing BILAG 2004 Index evaluat ions must be 
trained and cert ified before conducting study assessments. 
The BILAG 2004 Index is a clinical measure of lupus disease act ivity reported in 9 
body  systems. The BILAG score is based on clinical presentations of present, new, 
worse, the same, or improving, in compar ison to th e previous assessment. General 
BILAG cate gories are as foll ows: 
BILAG A: The presence of one or more serious features of lupus. 
BILAG B: Moderate features of the disease. 
BILAG C: Mild symptomat ic features. 
BILAG D: Prior activit y with no current symptoms due to active lupus. 
BILAG E: An organ that has never been invo lved.
The following sect ions also contain this change Footnotes to Table 3.a, Table 3.b, Section 4.3.4.3 , 
Secti on 5.2.3 .
Rationale for Change: Considering the primary object ive of the study  is safety  and tol erabilit y 
and not efficacy, and given the number of SLE assessment tools current ly incorporated into the 
protocol , the BILAG assessment was determined to not be necessary  and was rem oved.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study ID TAK -079-2001 Page 110of 110
Protocol Incorporating Amendment No 01 19 February 2019
Change 18: Clarificat ion that the statist ical analysis plan will be prepared before database lock.
The primary  change occurs in Section 11.1
Deleted 
Text A stati stical analysis plan (SAP) will be prepared and finalized before unblinding of 
patients’ treatment and before database lock. This document will provide further 
details regarding the definit ion of analysis variables and analysis methodology  to 
address all study  object ives.
Rationale for Change: To provide clarificat ion that the statist ical analysis plan will be prepared 
before database lock. 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use